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5CHAPTER'
1
ABSTRACT
Bayesian Model Selection Approaches are flexible methods that can be utilised to in-
vestigate Genetic Association studies in greater detail; enabling us to more accurately
pin-point locations of disease genes in complex regions such as the MHC, as well as
investigate possible causal pathways between genes, disease and intermediate pheno-
types. This thesis is split into two distinct parts. The first uses a Bayesian Multivariate
Adaptive Regression Spline Model to search across many highly correlated variants to
try to determine which are likely to be the truly causal variants within complex genetic
regions and also how each of these variants influences disease status. Specifically, I
consider the role of genetic variants within the MHC region on SLE. The second part
of the thesis aims to model possible disease pathways between genes, disease, inter-
mediate phenotypes and environmental factors using Bayesian Networks, in particular
focussing upon Coronary Heart disease and numerous blood biomarkers and related
genes.
1Bayesian Multivariate Adaptive Regression Spline Model
Genetic association studies have the problem that often many genotypes in strong link-
age disequilibrium (LD) are found to be associated with the outcome of interest. This
makes it difficult to establish the actual SNP responsible.
The aim of this part of the thesis is to investigate Bayesian variable selection methods
in regions of high LD. In particular, to investigate SNPs in the major histocompati-
bility complex (MHC) region associated with systematic lupus erythematosus (SLE).
Past studies have found several SNPs in this region to be highly associated with SLE
but these SNPs are in high LD with one another.
It is desirable to search over all possible regression models in order to find those SNPs
that are most important in the prediction of SLE. The Bayesian Multivariate Adapative
Regression Splines (BMARS) model used should automatically correct for nearby as-
sociated SNPs, and only those directly associated should be included in the model. The
BMARS approach will also automatically select the most appropriate disease model
for each directly associated variant.
It was found that there appear to be 3 separate SNP signals in the MHC region that
show association with SLE. The rest of the associations found using simple Frequen-
tist tests are likely to be due to LD with the true signal.
Bayesian Networks for Genetic Association Studies
Coronary Heart Disease (CHD) is one of many diseases that result from complicated
relationships between both genetic and environmental factors. Identifying causal fac-
tors and developing new treatments that target these factors is very difficult. Changes in
intermediate phenotypes, or biomarkers, could suggest potential causal pathways, al-
though these have a tendency to group amongst those patients with higher risk of CHD
making to difficult to distinguish independent causal relationships. I aim to model
disease pathways allowing for intermediate phenotypes as well as genetic and environ-
mental factors.
2Statistical methodology was developed using directed acyclic graphs (DAGs). Disease
outcomes, genes, intermediate phenotypes and possible explanatory variables were
represented as nodes in a DAG. Possible models were investigated using Bayesian re-
gression models, based upon the underlying DAG, in a reversible jump MCMC frame-
work. Modelling the data this way allows us to distinguish between direct and indirect
effects as well as explore possible directionality of relationships. Since different DAGs
can belong to the same equivalence class, some directions of association may become
indistinguishable and I am interested in the implications of this.
I investigated the integrated associations of genotypes with multiple blood biomark-
ers linked to CHD risk, focusing particularly on relationships between APOE, CETP
and APOB genotypes; HDL- and LDL- cholesterol, triglycerides, C-reactive protein,
fibrogen and apolipoproteins A and B.
Overview
I will begin by introducing the topics of genetics, statistics and directed acyclic graphs
with a background on each (Chapters 2,3 and 4 respectively). Chapter 5 will then de-
tail the analysis and results of the BMARS model. The analysis and results of Bayesian
networks for genetic association studies will then be covered in Chapter 6.
3CHAPTER
2
BACKGROUND TO GENETICS
The material in sections 2.1 - 2.4 is all referenced from Molecular Biology of The Cell
by Alberts, Johnson, Lewis, Raff, Roberts & Walter [1], An Introduction to Genetic
Analysis by Griffiths, Miller, Suzuki, Lewontin & Gelbart [2] and Essentials Of Med-
ical Genomics by Brown [3].
Genetics is the key to heredity and variation in living organisms. Genetic information
is stored in the nucleus of most cells of an organism. This information is both copied
and passed onto offspring (through replication of DNA); and translated into proteins
(used for different functions within the organism). These processes are described in
more detail below.
2.1 DNA, Chromosomes and Genes
Genetic information is transmitted and stored as deoxyribonucleic acid (DNA). DNA
is made up of strings of polymers called nucleotides, or bases. Nucleotides come in
4four types: adenine (A), cytosine (C), guanine (G), and thymine (T). These strings of
nucleotides form a double helix and the nucleotides on each strand pair with the one
opposite via hydrogen bonds. A pairs with T, and C pairs with G. Therefore, one strand
completely defines the other and just one of the complementary bases will define the
nucleotide type at any given position along the DNA chain.
Figure 2.1: DNA double helix [4]
The genome is the complete set of genetic information contained in the DNA of an
organism. A gene is a unit of heredity which carries information from one generation
to the next.
This information is stored on very long units in which DNA is packaged called chro-
mosomes. Chromosomes are all packed together very tightly in the cell nucleus. Other
than gamete cells (see below) humans have 46 chromo omes in each cell nucleu - one
pair of sex chromosomes and 22 pairs of autosomes (non ex chromosomes) . In re-
production, each parent provides an offspring with one chromo orne of each of their
23 pairs. Gamete cells are sperm and egg cells and have 23 single chromosomes (hap-
loid), rather than 23 pairs (diploid). In reproduction, gamete cells fuse with gamete
cells from the opposite sex.
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Figure 2.2: Successiveenlargementsof an organismto focuson thegenetic material[2]
2.2 Replication, Transcription & Translation
When DNA replicates the double helix structure unwinds and splits into two strands.
Each single strand of DNA acts as a template for the production of a new strand with
complementary bases. These new strands pair with their templates and form two dou-
ble stranded helix molecules of DNA identical to the original (barring any novel ge-
netic variation).
As mentioned before, genes are functional regions of DNA. The genetic information
stored in DNA can also be translated into protein. Producing proteins from informa-
tion in a DNA gene is a two step process. The first step is called transcription, and
involves the synthesis of a riboneuclic acid (RNA) chain that is complementary to one
of the strands of DNA. RNA is similar to DNA, and is made up of a string of bases: A,
C, G & Uracil (U), instead of T. RNA has the same complementary bases as DNA (A
pairs with U). To transcribe the information in DNA, the double helix separates, and
one of the strands acts as the template to form a complementary strand of RNA.
The second step in producing a protein from DNA is called translation, and involves
using the information in RNA to produce protein. Proteins are responsible for many
functions in the cell. For example, they act as enzymes or structural components, and
they are essential in building muscle, skin, bone and blood.
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Figure 2.3: Steps in Producing DNA and Proteins
2.3 Mendelian Laws of Inheritance
A locus is a particular position along the genome and can refer to a single base or
longer region. Genes relating to a particular trait (eg. eye colour) are located at the
same locus on the same chromosome in each individual. Every individual has two of
every chromosome (one from each parent) and therefore two of each locus. Alleles
are different possible forms of the locus. Each individual can only have two alleles for
each locus. These can vary between individuals. A phenotype is a detectable outward
manifestation of a gene. For example, the gene for the phenotype eye colour has alleles
that result in blue, brown or green eyes.
As mentioned above, offspring inherit one chromosome of a pair from each parent.
Mendel's principle of segregation states that the allele inherited from each parent for
each characteristic is random with equal probability. In the diagram 2.4 below, two in-
dividuals have alleles M I, M2 and M3, M4 respectively for marker 1and 2 for parent 1
and 2. These alleles could each be A,T,C or G. These alleles separate from each other,
and then combine with another allele from the other parent. The combination of these
alleles is random with equal probability. The possible allele combinations from these
two parents are MIIM3, MtIM4, M2IM3 or M21M4. Each allele combination occurs
with 25% probability, assuming the alleles are not linked.
7Figure 2.4: Different Allele Combinations from Two Parents
The combination of unordered alleles at a particular locus is known as a genotype. If
an individual has two of the same allele for a particular trait then it is known as ho-
mozygous. However, if an individual has two different alleles then it is heterozygous.
For example, in the stretch of DNA shown below in Table 2.1, shows the two chromo-
somes one above the other, for a segment of DNA made up of ten base pairs. The third
base pair is highlighted and two different alleles are possible at this locus (namely A
and T). The individual is heterozygous at this locus.
T G A A A G A C C A
C c T G T C A G C T
Table 2.1: Example of Genotypes
Suppose that only two alleles (A and T) are possible at this locus. The genotype of
the highlighted locus is Aff, but could be NA (homozygous) or TfT (homozygous)
in a different individual. Note that a genotype is unordered so that Aff and T/A are
equivalent.
2.3.1 Hardy-Weinberg Equilibrium
In generalised terms, if we have a single locus with two possible alleles, Al with prob-
ability p, and A2 with probability (l-p) in a population, the expected frequencies are
8shown in Table 2.2 below:
Mother
Father AI(p) A2(1-p)
AI(p) AIA1(p2) A1A2(p(1-p»
A2(l-p) AIA2(P(l-P» A2A2((l-p )2)
Table 2.2: Frequencies of Alleles Inherited under Hardy-Weinberg Equilibrium
These frequencies are expected under the assumption that individuals in a popula-
tion are randomly mating and therefore diploid genotype (genotypes with information
about both alleles rather than genotypes coded as 0,1,2 as described later) frequencies
should only depend on allele frequencies in the population. For example, if the allele
frequency of Al is 0.9 and that of A2 is 0.1 then the expected genotype frequency of
AI/AI is 0.81, AdA2 is 0.18, and A2/A2 is 0.01. If the observed genotype frequen-
cies (calculated as described above) follow these probability expectations then this is
known as Hardy-Weinberg equilibrium (HWE). HWE is usually tested by using a
chi-squared test, comparing the observed genotype frequencies with those expected
under HWE. If the genotype frequency deviates from HWE for a particular locus then
this may be due to several reasons including genotyping errors, sampling variation, and
non-random mating. Therefore, HWE tests are often used as a form of quality control
test for genotype data and to check whether assumptions made in subsequent analyses
are reasonable.
2.4 Haplotypes and Recombination
A haplotype is a combination of alleles transmitted together at multiple loci on the
same chromosome. If there are two different alleles possible at each of two loci (for
example alleles Al and A2 at locus 1 and B, and B2 at locus 2) then there are four
possible haplotypes (AI-B1, AI-B2, A2-BI and A2-B2)' Each individual will have two
haplotypes (one on each strand).
9Occasionally when chromosomes pair during meiosis (the process of forming ga-
metes), the chromosomes exchange segments/strands during a process called crossing-
over. This results in new combinations of alleles called recombinants. Recombinants
can cause offspring to have haplotypes not seen in the parents. Figure 2.5 demonstrates
crossing over of parental chromosomes to form those for the child. The blue chromo-
some is that taken from the father, and the white is taken from the mother.
a a
b b
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a a
b b
a
Gametes b
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v e
crossmg-over and recombination during meiosis
Figure 2.5: Recombination of Chromosomes [5]
It is possible for more than one cross over to occur between two loci.
The recombination fraction is the proportion of offspring that receive a recombinant
haplotype from their parents ..Usual genotyping methods cannot determine haplotypes
directly since genotyping only reports the unordered alleles at each locus and does not
report which strand each allele belongs to. If an individual has genotypes Al/A2 and
Bl/B2 it is not possible to determine whether the haplotypes present are A1-B1 and
A2-B2 or Al-B2 and A2-B1. If, however, we have a sample of individuals, it is possible
10to estimate the frequencies of each haplotype based on their genotypes and the sample
haplotype frequencies. The haplotypes can be imputed using haplotype phasing tech-
niques as discussed in Section 2.7.3.
2.5 Linkage Disequilibrium
When alleles at different but nearby loci are statistically associated they are said to
be in linkage disequilibrium (LD). Another way of putting this is that LD exists if
there is departure from the expected haplotype frequencies if the loci were inherited
independently. LD typically exists between two nearby loci that have been inherited
together over many generations [6]. Figure 2.6 below shows a stretch of DNA inherited
from common ancestors over time. The blocks of yellow are alleles in LD inherited
together over many generations. The blue blocks arenew alleles introduced by recom-
bination.
Anoostral
ChromosotT1e
Presen1-day
chromosomos
Nature Reviews IGenetk:.
Figure 2.6: Linkage Di equilibrium [7]
11Whilst the association between two alleles located next to each other will break down
over time due to recombination; it may be maintained over many generations if recom-
bination is low. The two main measures of LD are based on the statistic D. Suppose
I
we have two loci with major alleles Al and Bit and minor alleles A2 and B2' A minor
allele is one which is the least common for a particular genotype in a given population
whereas a major allele is the most common one. Al has population frequency p, and
Bl has population frequency q. Assuming no LD, and alleles occurring independently,
the expected haplotype frequencies are shown in the table below.
Haplotype Al A2
Bl pq q(l-p) q
B2 p(l-q) (l-p)(l-q) l-q
P I-p 1
Table 2.3: Haplotype Frequencies assuming no LD (i.e. independence of inheritance)
Let e be the observed haplotype frequency of AlBl. D (a measure of LD), is defined
by D=e-pq=o. D is a measure of LD which is defined as the departure from the fre-
quencies under independent inheritance Ho. We expect that ()= pq when both alleles
are inherited independently so that D=O. If LD exists then the haplotype frequencies
in the above table no longer hold true and D can lie between -1 and 1.
Haplotype At A2
Bl pq+ D q(l-p) - D q
B2 p(l-q) - D (l-p)(l-q) + D l-q
p l-p
Table 2.4: Haplotype Frequencies with LD
Given observed data of p and q and haplotype frequencies, it is simple to estimate D,
the measure of LD.
12D' and r2 are the usual measures of LD. They are both diallelic measures and are both
used in this PhD thesis.
D depends on the frequency of alleles. D' is a normalised measure, achieved by divid-
ing D by the theoretical maximum given the observed allele frequencies.
D' = _E__
Dmax
(2.1)
where
min(p(l - q), (1 - p)q)
min(pq, (1 - p)(l - q)
ifD > 0
otherwise
r is defined by
D
r = -y';=p(;=l =_::::;:p ):::::;q(=l _===:=q)
r2 is the correlation coefficient and is a measure of similarity between two markers
with respect to their minor allele frequencies (MAFs). A measure of r2 = 1 or D' = 1
between two loci represents "complete" dependency, whereas r2=0 or D' =0 between
two loci indicates independence.
(2.2)
Although the values of r2 being 0 or 1and D' being 0 or 1can be interpreted the same
way in terms of independence, the relationship between the two measures of LD is not
that simple. D' = 1when one of the four possible haplotypes is not observed indicating
there has been novel genetic variation but not recombination. When D'=1this does not
imply that r2 will also be 1. They are only equal when both 0-0 and 1-1 haplotypes do
not occur, or both 0-1 and 1-0 do not occur. D' is usually used to measure the extent
of recombination between loci over several generations, whereas r2 is usually used
to measure similarities between loci, and quantify how well one locus can predict the
value of another.
13Genetic association studies often have the problem that many genotypes in LD are
found to be associated with the outcome of interest. This makes it difficult to establish
the actual SNP responsible. This problem will be discussed more in chapter 5.
2.6 SNPs
Single nucleotide polymorphisms (SNPs) occur when a single nucleotide (A,T,C or
G) varies between individuals at the same marker. e.g. instead of an A allele there
is sometimes a C. The minor allele is that which has the lowest frequency at a locus,
usually of two alleles (biallelic) [1]. Figure 2.7 below shows an example of a SNP
between two chromosomes.
------- SNP --------------
Figure 2.7: Example of a SNP
142.7 UsesofLD
2.7.1 International HapMap Project
The International HapMap project [8] started in 2002 and aims to better understand
LDI haplotype structures. By analysing the patterns of variation in the genome, it is
hoped that this information could be used to identify genes associated with complex
diseases. "Genetic data from more that one population will enhance the ability of re-
searchers to study the genetic contributions to diseases that are more or less prevalent
in different groups."
The HapMap project has collected DNA from 270 people from 4 main populations:
U.S. residents with northern and western European ancestry; Yoruba residents from
Ibadan, Nigeria; Japanese individuals from Tokyo and Chinese individuals from Bei-
jing. The DNA was used to type approximately 1 million SNPs. Due to the success
of the first phase, the study was extended. The second phase used these blood samples
to type three times as many markers and was published in 2007. [9] The third phase
increased the number of samples from 270 to 1,301 and includes a wider variety of pop-
ulations. These are those with African ancestry in Southwest USA; Utah residents with
Northern and Western European ancestry(as before); Han Chinese in Beijing (as be-
fore); Chinese in Metropolitan Denver, Colorado; Gujarati Indians in Houston, Texas;
Japanese in Tokyo, Japan (as before); Luhya in Webuye, Kenya; Mexican ancestry in
Los Angeles, California; Maasai in Kinyawa, Kenya; Toscani in Italia; and Yoruba in
Ibadan, Nigeria (as before). [10]
It is hoped that these populations will help to identify the most common haplotypes
worldwide, and help in analysing variation between them. HapMap can be used to
view genome information e.g. in haplotype blocks of LD. From this, it is possible to
analyse which loci represent most of the underlying variation of the genome. HapMap
can act as a reference panel for imputation (detailed under 2.7.3) of loci that may have
been untyped in a particular study based on unobserved genotypes at nearby loci.
HapMap has helped us better understand the underlying genetic structures across pop-
ulations including LD structure.
152.7.2 Tagging
Regions of high LD between loci means that we only need to type a small subset ofthis
region to represent it genetically. We can gain the same amount of genetic information
by genotyping a smaller subset. The aim of 'tagging' SNPs is to select those that will
best represent the genome or region of interest. [11-14]
2.7.3 Imputation
Genotypes at a particular locus may be missing for several reasons. They may have
simply not been typed for the study in question, there may have been a genotyping er-
ror, or maybe a reason specific to that allele/locus. Missing genotypes can lead to loss
of power and sometimes this missing data can lead to incorrect results due to bias [15].
Imputing missing information leads to a higher mapping density of data. Imputation
can increase the power of genetic association. [16]. Imputation can also aid in fine
mapping since denser loci can be imputed based on those tagged to be representative
of a region of LD. Each locus can then be used for association analysis whether or not
they have been typed in the study in question or imputed.
It is common that different studies will type different SNPs across the region of in-
terest. Pooling results can give a better picture and add more power to analyse which
variants within a region have the largest effect. If not all loci are typed in each study,
imputation can help fill in the missing data. It has been shown that studies with weak
findings can be combined together using these methods to identify completely new and
highly significant variants.
In terms of imputation, a cluster is a group of loci in high LD. These clusters vary by
size along the chromosome.
The program used in this PhD for imputation, Mach [17], makes use of a Hidden
16Markov Model (HMM) in updating the EM algorithm to find a maximum posterior
distribution. This model states that the unobserved cluster locus depends only on the
(unobserved) cluster which the previous locus belongs to.
Mach is one of the most commonly used imputation programs used for large datasets
such as GWAS [18]. Mach has been shown to perform as well as other programmes
also suitable for large datasets in terms of accuracy and computing time. [19-22]
Mach has the option of calculating the average allele dosage score for each SNP im-
puted. There is also the option of estimating LD of the imputed SNP with non missing
loci.
2.7.4 RareVariants
It has historically been difficult to detect rare variants due to the tagging of representa-
tive SNPs in LD. These tagged SNPs do not represent rarer SNPs well. Whole genome
sequencing will hopefully provide more information on these. For example, the 1000
Genomes Project [23]. These types of genotyping collection are possible now the cost
of genotyping has significantly reduced in recent years. It is hoped that the information
gained by analysing rare variants will help us to better understand complex diseases as
we will have a clearer picture of the whole genome.
2.8 Genetic Association Studies
Genetic association studies can be used to determine whether there is an association
between a genotypic variant of interest and a disease or trait. For a binary disease
outcome (eg. disease/ no disease) and a case control study design, this is done by com-
paring genotype or haplotype frequencies at the locus of interest by outcome group.
Under the null hypothesis of no association, the genotype frequencies between cases
and controls should be equal. A case-control study compares a risk factor across two
groups; one with disease (cases) and one without (controls). In association studies the
17risk factor is the genotype variant [6]. A simple test for association is, for example, to
use logistic regression of case status (y) on coded genotype classes:
(2.3)
(2.4)
where Yi defines the case status for individual i (0 for control, 1 for case), tri is the
probability of individual i being a case, a is the intercept, Xi is the genotype variant of
subject i; usually coded 0 for first homozygous genotype, AlA for example, 1 for the
heterozygous genotype, AIT for example, and 2 for the other homozygous genotype,
Trr for example, and f3 is the genotypic effect on probability of disease. This is an
additive model on the log scale as the odds ratio (OR) for Trr is twice that of Arr i.e.
each T allele increases the OR by an equal amount. Other models can be considered to
allow for a dominant or recessive effect of the genotype, as described below.
Under a dominant model, only one copy of the variant allele is required to cause an
increase in risk of the disease. Having two copies of the variant allele is assumed not
to increase that risk. i.e. P(DIAA) = P(DIAa).
(2.5)
Under a recessive model, both copies of the variant allele are required to cause an in-
crease in risk of the disease. P(Dlaa) = P(DIAa)
(2.6)
Under a 2 degrees of freedom (2dJ.) model, the increase of risk of disease by having
two copies of the variant allele is different to that of having only one copy, but not in
an additive way.
18(2.7)
The appropriate test of association now has 2d.f. and tests against the null hypothesis
which in this case is j3 = 0 & 'Y = O. j3 can be viewed as the additive genetic com-
ponent and 'Y as a dominance (or equally recessive) component or the deviation away
from the additive model.
Itis possible to show the genotype data for each SNP in a simple contingency table, as
shown below.
Genotype Cases Controls Total
Observed Expected Observed Expected
0 nOCa ~
nOCon
nQ.n Can no. n.. n..
1 nlCa !!.l.!!..!&.
nlCon
nl n Call nl, n.. n..
2 n2Ca ~ tizcs«
11,~.n QQ:ll
11,2. n.. n..
Total n.Ca ~
n.Con !L.!!...C.= 11,
11.. n.. ..
Table 2.5: Contingency Table for One SNP
Under the null hypothesis of no association with the disease, it is expected that the
genotype frequencies are the same in cases and controls. A 2d.f. score test for associ-
ation can be calculated using Pearson's X2 statistic for independence of the rows and
columns given by
X~en= L L
i=O,1,2 j=Ca,Con
(nij - E[nu])2
E[nul
(2.8)
E[ 1
nl.n.J
nij =--
n..
(2.9)
19Under the null hypothesis of no association (independence between the rows and
columns of the table above) of SNP and outcome, the test statistic has an approxi-
mate X2 distribution with two degrees of freedom.
2.8.1 Fisher Exact Test
An alternative to the Pearson's X2 test is the Fisher exact test which avoids relying
on asymptotics. This is especially useful when SNPs have small frequencies of geno-
types. In addition, a Fisher exact test does not assume an additive model, and allows
for any type of association between the SNPs and outcome. It may not be that all SNP
associations are additive, and this test gives more flexibility by SNP. In this framework,
each SNP is tested for an association individually. The Bayesian Multivariate Adaptive
Regression Spline model I use later (5.9) has a dominance component for such flexi-
bility, and using a Fisher exact test for my frequentist analysis allows for more direct
comparisons to be made under the different methods.
As explained above, genotypes can be coded as 0, 1 or 2 (two copies of the minor
allele, one copy of each the minor and major allele, or two copies of the major allele).
Itis possible to show the genotype data for each SNP in a simple contingency table, as
shown above.
Under a Fisher exact test [24] the probability of obtaining the observed values in the
table above is given by the hypergeometric distribution. This probability is given by
p= (2.10)
202.8.2 Data Augmentation in Binary Probit Regression
In order to simplify modelling a binary outcome, a probit link function with data aug-
mentation can be used.
By introduction of latent variables (via data augmentation) it is possible to reduce a
test of association with a binary outcome to a Gaussian linear model [25]. Consider
(2.11)
where
K
'T] = al +I:f3kx
k=l
In the probit model, the mean is given by /-Li = CP(1]i) so it follows that the probit link
function g(/-Li) = cp-l(1]i)
(2.12)
Introducing a set of latent variables Wi for the ith observation with a Gaussian distri-
bution conditional on observation specific random terms.
(2.13)
such that
y;= {
1 if Wi > 0
o otherwise
Therefore, the distribution of Yi having integrated out Wi is
21P(Yi = 1) - P(Wi > 0) = P(N(rJi' 1) > 0)
- P(N(0,1) > -rJi) = P(N(O, 1) < rJi) = q>(rJi)
(2.14)
2.9 Potential Problems with Genetic Association Stud-
ies
As explained in Section 2.3, genotypes are passed on to offspring under Mendelian
randomisation. This means that genotypes are inherited at random with equal proba-
bility. Genotypes are invariant to mRNA, proteins, diseases and environmental factors.
Therefore, genetic associations should be protected from reverse causation as these
things cannot cause a particular genotype. In addition, environmental factors cannot
be considered as possible confounders in a genetic association test which is a possible
problem with other association tests.
However, genetic association studies can still suffer from selection bias. For example,
in population based association studies, it is necessary to ensure that the cases and
controls have the same ethnic background otherwise a gene that differs between ethnic
groups could appear to be associated with the disease if disease prevalence differs in
the two populations.
Another potential problem is that two loci could be so closely in LO with each other
that they both appear to be equally associated with the disease outcome. In this case
it can be hard to determine which locus is truly associated with the disease by consid-
ering just the single SNP association tests. More complicated approaches that try to
correct for the effect of other loci are required to understand the data more clearly.
Finally, there is the problem about which disease model to assume. Often the additive
model is used but this can lead to loss of power when this model is incorrect, especially
in the recessive case. Methods that do not force a particular model are desirable.
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3
BACKGROUND TO STATISTICAL
THEORY
The majority of this Chapter is referenced from Bayesian Data Analysis [26], Markov
Chain Monte Carlo in Practice [27] and Markov Chain Monte Carlo: Stochastic Sim-
ulation for Bayesian Inference [28] unless otherwise stated.
3.1 Statistical Inference in a Frequentist Setting
In classical or frequentist statistics, observed data Xex are used to make inferences
about a population parameter (J which we consider to be fixed, i.e. true but unob-
served. One approach to estimate ()in a frequentist setting is via likelihood modelling.
Suppose that Xl, ...,Xn are observable random variables with ajoint distribution that
depends on unknown parameters 8= «()1, ... , ()d). The likelihood function of 8is found
by evaluating this distribution at the observed data (sample) x=(xt, ...,xn), f(xI9).
Note: This is not a probability distribution for 9 as it does not sum to lover ().
23As the data x are known, we are only interested in how the likelihood varies with (J.
Arguably the best estimator of the true value of (J is that value of (J which maximises
the likelihood function. This estimator, ii, is known as the maximum likelihood esti-
mator. [29-32]
.....
Inference can take the form of a point estimate (for example, 0=0.1); a confidence
interval (range in which 0 will lie within with a specified probability); a hypothesis
test (for example, reject the hypothesis that () < 0.07 at the 5% significance level);
a prediction (predict that 15% of patients will have an adverse event); or a decision
(decide to stop treatment on patients with adverse events). In each case, knowledge of
the observed sample value X=x is being used to draw inferences about the population
characteristic (). Moreover, those inferences are made using the likelihood function,
f(xl(J), which determines how, for a given value of 0, the probabilities of the different
values of X are distributed. In this setting of frequentist statistics, the statistical param-
eter, (J, although it is unknown, is treated as a constant to be estimated rather than as
a random variable.
3.2 BayesianInference
Bayesian inference allows us to combine the knowledge from observed data, and any
prior knowledge we may have before the sample is collected. It also allows us to make
inference about the distribution of the parameter values.
The fundamental difference between frequentist and Bayesian statistics is that in a
Bayesian context, 9 is treated as a random (vector) variable. Before collecting data on
the random variable X (which possibly depends on (J), the distribution of 9 is believed
to have prior density f(9). The probability distribution of (J is updated given the ob-
served data (j(xI9), using Bayes theorem, to give the posterior distribution f(9Ix),
which is the probability of the parameter (J given the observed data x. Inference is
based on the posterior, rather than the likelihood.
24Bayesian statistics revolves around Bayes theorem, which defines the posterior distri-
bution as:
where f(O) is the prior density, encompassing our prior beliefs about e, and f(xIO) is the
likelihood; the same as that used in frequentist inference outlined above. J(f(O)f(xIO)dO
is the normalising constant used to make f(elx) a probability density (i.e. sum to 1).
This normalising constant often does not need to be defined explicitly since f(O)f(xIO)
includes all the information about 0; the random vector we are interested in making in-
ferences about.
The prior distribution, f(9), which represents our prior knowledge or beliefs about 9
could be, for example, obtained from results of previous studies, or from expert opin-
ion.
Consider a simple example. If we have three experiments:
1. A tea-drinker claims she can tell whether the milk was added before or after the
tea. Out of ]0 attempts, she is correct 10 times.
2. A music expert claims she can identify and name any piece of Mozart's work.
She correctly identifies 10 out of 10 pieces.
3. A drunk friend claims she can predict the outcome of the toss of a fair coin, and
does so 10 times in a row.
In all of the above, the model is f(XIO) '" Bin(lO, 0) and x=10 is observed.
In frequentist statistics, using f(xIO), we would make the same inferences about 0 in
each case. Opinions differ as to whether this is either a draw back or an advantage of
inference in a frequentist setting. Our prior beliefs are likely to be different in each of
the above situations. Our prior beliefs are likely to remain highly skeptical about 3,
25partly convinced by 1, and perhaps not surprised by 2.
It can sometimes be difficult to express prior beliefs, and an uninformative prior might
also be used in this case.
3.3 Inference
If a posterior distribution has the same parametric form as the likelihood distribution, .
for the parameters of interest, then the prior is known as a conjugate prior. Conjugate
priors are often convenient. For example, if the prior distribution is Gaussian, and the
observed data has a likelihood distribution that is also Gaussian with known variance,
then the posterior distribution is also Gaussian. In this case, there is no need to cal-
culate the constant of proportionality of the full posterior distribution because this is
already known from the distributional form. [26]
Suppose we have data Y=(Yl, ... , Yn) that are i.i.d, with Gaussian distribution with
likelihood
(3.1)
where the variance a2 is assumed to be fixed at some known value. With a Gaussian
prior with mean /-to and variance T~, the posterior is also Gaussian:
p(OIY) oc p(O)p(YIO)
n
= p(O) IIp(YiIO)
ex: exp( __ l (O-J-lo)2)II
n
exp( __ l (Yi-O?)
27,2 2u2
o i
ex: exp( -~[_!_(O - J-lo)2+ _!_ ~(Yi _ 0)2])
2 7,2 u2 L- o i
(3.2)
26leading to
(3.3)
However, it is not always possible to find a conjugate prior distribution that fits our be-
liefs, or perhaps a conjugate distribution is not known for the likelihood of interest. In
non conjugate settings the implementation of Bayes Theorem can be computationally
difficult, usually as a result of having to calculate the normalising integral in the de-
nominator. Calculating this normalising integral is necessary if we want to make most
inferences or predictions from the posterior distribution. Calculating this integral can
be extremely computationally intensive. As mentioned above, for some choices of the
prior distribution, calculating this integral can be avoided, but in general, specialised
techniques are required to perform this calculation. i.e. Inference from the posterior
distribution can be done either algebraically, or computationally using sampling. One
such method of sampling is Markov Chain Monte Carlo (MCMC).
3.4 Markov Chain Monte Carlo
Markov chain simulation algorithms allow us to sample from the posterior distribution
when calculating its full distribution is algebraically difficult. i.e. when the result-
ing posterior distribution is non-tractable. MCMC methods simulate a Markov chain,
whose stationary distribution is the posterior distribution we are interested in. [28,33]
A Markov chain is a sequence of random variables Zl,Z2,Z3, ... with the property that
at each time point t, the next state Zt+l is sampled from a distribution dependent only
on the current state Zt. The possible values of Z; form the state space, S. This is called
the Markov property: given the present state, the future and past states are independent.
27Under certain conditions (see below), the Markov chain converges to a stationary dis-
tribution that is, one which does not change over time. This stationary distribution does
not depend on t or Zoo
A chain converges to a stationary distribution if it satisfies all three of following con-
ditions [28.34]:
1. It is irreducible: there is a probability that the chain can assign any possible
member of state space S to Z; in a finite number of iterations.
2. It is aperiodic: the chain does not cycle between a subset of values for Z, in a
regular periodic movement.
3. It is positive recurrent: given any initial value of Zt, the expected number of
iterations to return to that initial value is finite.
Note: Each of these conditions by themselves is necessary.
In MCMC, we simulate from the "target" (posterior) distribution, making enough
draws so the distribution of draws is hopefully "close enough" to the stationary dis-
tribution. Once the stationary distribution has been achieved, future draws from this
distribution are still dependent since every new draw is now sampled conditionally on
the previous state.
When simulating using MCMC algorithms it is required to check convergence with
plots, summaries, and then delete the first M simulated values as a bum-in period. The
burn-in period is the time which it takes the algorithm to reach a stationary distribu-
tion. Once we are satisfied the data has converged, the target (posterior) distribution
can be summarised by the simulated values ofe drawn after this point. For example,
an approximation to the mean of the distribution can be found simply by taking the
mean of the simulated values ofe.
283.5 Metropolis Hastings Algorithm
One such example of a MCMC algorithm is the Metropolis Hastings (M-H) algorithm.
Suppose we have a vector (J of dimension d of parameters we wish to sample. The
basic outline of a M-H algorithm is to
1. Select a starting point for vector (J
2. Propose a candidate value of (J for the next step of the Markov Chain
3. Accept the proposed value of (J given the rule below
4. Repeat the steps iteratively
In general terms, the chain is initialised with O?,... ,O~. Now suppose the current values
of the chain is 0{,... ,O~and that we want to simulate o{+l, the next value of 01, The
general scheme of the MCMC is to update O{ to o{+l and accept the new value using
the acceptance rule below.
Schematically the general Metropolis-Hastings updating mechanism is:
• Propose a candidate value o~an, which is a drawn from an arbitrary distribution
with density q(Oianl{l{, (I~, ... , ~).
• Take as the next value of 01 in the chain
'+1 { Oi =
0{
oean
1 with probability p
with probability I-p
where
p = min (1 p(OfaR,o~, .."oal:r) q(o{ IOlaR,O" ,Ii~»)
, p((Jl,~, ...,(}~lx» q(lifanl~,Ii~, ,~)
with p(Oin,~, ... ,0~lx) denoting the posterior distribution of {II evaluated at
{l1 = {lin and similarly for p( {I{, (I~, ... ,~Ix) evaluated at {l1 = o{.
29• Update each member of (), proposing e~an,()jn, etc. in this way
• Iterate this procedure
The candidate generator q(einle{, e~,... ,e~) is arbitrary but some choices of q(.) will
lead to faster convergence, and are therefore more computationally efficient. The vari-
ance of the candidate distribution is an important choice because if it is too big then the
proposed moves will be too large, and acceptance probabilities will be low. However,
if variance is chosen to be too small then then the acceptance probabilities will be high
but only small steps will be taken, and convergence will be slow.
Note: a common choice for the candidate generator is the density of a Gaussian distri-
bution for ein with mean e{. This is known as the Random Walk Metropolis Hastings
algorithm. Due to the symmetry of this candidate generator, the terms in the accep-
tance probability involving q(.) cancel and this reduces to
p= min(1, ratio of posterior distribution of ()}anvs 8{)
It can be shown that the Metropolis-Hastings algorithm converges to a stationary dis-
tribution, equal to the target posterior distribution.
3.6 BayesFactors
Bayes Factors CBF) are increasingly used in genetic epidemiology as an alternative to
frequentist p-values. If we have a discrete set of possible models, a Bayes Factor is
the ratio of posterior to prior odds of one model compared to another. If we wish to
compare two models M, and M, the Bayes Factor is defined as
(3.4)
where D is the data given. , If the two models have equal prior probabilities then
P(Mi)/p(A/j) = 1 and BF(Mi• !It!j) is simply pf~;I~~ [26] , [35], [36]
30For example, a Bayes Factor can be used to test one model against the null hypothesis
in a linear regression that (3 = O. BFs > 3 are usually interpreted as an indication of
evidence in favour of Mi. [37]
3.7 Reversible Jump Metropolis Hastings Algorithm
Sometimes we wish to sample over models with varying dimensions. For example,
with regression models. it is likely that we will want to select the most important
predictors among a sometimes large set of variables. As in genetic applications, for
example.
One solution to this is to sample over the model space, and treat the model structure
(which variables, and how many) as an additional, separate parameter, say ~. We are
then interested in the posterior distribution of this parameter. For example, consider a
simple regression model with 10possible explanatory variables. If we were to propose
the first, third and eighth variables in the model, the parameter space for this iteration
could be defined by e=(1,0,1,0,0,0,0,1,0,0) where 1 indicates the inclusion of the cor-
responding explanatory variables (say, f3).
The Reversible Jump MCMC [34,38] scheme deals with this. The Reversible Jump
algorithm is an extension of the Metropolis-Hastings algorithm, and samples from pos-
teriors of varying dimension. At each step of the algorithm, we propose to either add
a variable to the current model (increase the dimension of corresponding explanatory
variables (3 by 1) which is known as a 'birth' step, or drop one (decrease the dimen-
sion by 1) which is known as a 'death' step. Note: At each iteration, a new value is
proposed for the element of /3 relating to the variable in question. i.e. a new value is
randomly proposed when adding a term, but is simply forced to 0 if dropping the term.
These steps are chosen at random, and the proposed vector of parameter space ee') is
accepted with probability
min (1, likelihood x prior x proposal ratio)
31For example, if a birth step is proposed the acceptance probability is
where dk is the probability of dropping one element of e and bk is the probability of
adding one element of e. If bk= dk = 0.5 then the acceptance probability is simply
min(l,BF(e', e».
Note: The above acceptance probability also includes a Jacobian term to account for
the change in dimension between a model with parameter space e and e' but in practice
this is rarely needed. [34]
In this situation, the MCMC algorithm is set up to combine a Reversible Jump algo-
rithm to move in model space, e (e' is accepted with above probability), and then a
M-H sampler as described in Section 3.5 to draw values of the current corresponding
explanatory parameters in the model, /3.
By monitoring both e and /3, this algorithm would give posterior probabilities of the
models visited as well as the usual posterior distribution of model parameters. Itis then
possible to decide the importance of each predictor by summing the posterior probabil-
ities of the models containing the relevant term. This gives the marginal probabilities
of each predictor. It is also possible to examine the joint probabilities of variables.
MCMC schemes rely on being able to sample parameters conditional on the value of
others. Directed acyclic graphs (DAGs) represent such dependencies naturally and
conditional independence structures can be represented graphically. We discuss this in
the next chapter.
32CHAPTER
4
INTRODUCTION TO DIRECTED
ACYCLIC GRAPHS
4.1 GraphicalModels
Graphical models are one way to present statistical relationships. Precisely, dependen-
cies between variables and indicating conditional independent structures, Using them
it is possible to represent assumptions about relationships between variables. Fitting
graphical models also helps to determine whether is it possible to identify directions of
association with the data available and they can highlight possible biases. In addition,
graphical models make it easy for the reader to understand or picture more complex re-
lationships and can help set up joint probability models for such complex data systems.
A graphical model has nodes representing variables. Any line or arrow connecting two
variables in a graph is called an edge. Edges can be directed (represented by a single-
headed arrow) to represent direct links from one variable to another; or non-directed
(usually represented by a dashed line). Edges represent direct associations between
33variables after accounting for all other variables in the graph. In the graphical model
below, for example,
B has a direct effect on D, D has a direct effect on C, A has a direct effect on C and A
and B are associated but direction of effect is not specified. The association between
Band C is entirely through A and D. i.e. indirect. [39]
A path in a graphical model is defined as a sequence of edges connecting one variable
to another. A path can have directed or undirected edges, and need not follow the di-
rection of the edges.
4.2 Directed Acyclic Graphs
A directed acyclic graph (DAG) is a graphical model with directed edges, and no closed
loops (i.e. for all variables in the graph there does not exist a directed path from a par-
ticular variable to itselt). For example, the graph below contains a cycle (A to D to C
to A), and is therefore not a DAG. [40]
34On the other hand
is aDAG.
4.3 DAG Terminology
Consider this simple example of a DAG:
Some simple terminology ofDAGs, using the above diagram as an example: [39,40]
35• Two variables are adjacent if they are directly connected by an edge. e.g. A and
B are adjacent, but A and D are not.
• A path through the graph is any unbroken route connecting adjacent nodes.
• A directed path through the graph is any unbroken route connecting adjacent
nodes by directed edges and following the direction of these edges e.g. A to B
toD
• A variable is known as an ancestor if there is a directed edge or path from that
variable to another. e.g. A is ancestor of B,D,e and E.
• A variable is known as a parent of another if there is a directed edge from it
to another adjacent. e.g. A is a parent to Band e. Band e are also said to be
directly affected by A.
• A variable is known as a descendant, or affected by another if there is a directed
path into that variable. e.g. D is a descendant of e.
• A variable is known as a child if there is a directed edge into that variable from
another. e.g. D is a child of B and E.
• A backdoor path is defined as one in which there the first variable in the path is
a child of the second, and there are 3 or more variables connected in the pathway
e.g. D to E to B.
• A collider is a node with at least two parents. e.g. D or B.
• A path is blocked or closed if it has one or more colliders on it. e.g. A to B to D
toE.
• A path is unblocked or open if there are no colliders on it. e.g. D to E to e is an
unblocked path. In this case it is also a backdoor path.
• A v-structure is a collider in which the parents of the colliding node are not
adjacent. The two parents have directed edges towards the same child, creating
a 'v'. e.g. the following DAG is a v-structure:
36In this given v-structure, A and B may be marginally independent as they do not
have an association between them directly, but they are dependent conditionally
on C as there is a pathway from A to B through C.
4.4 Using DAGs in Statistical Modelling
Quantitative statistical approaches can be used to translate DAGs into statistical mod-
els. For example, statistical models can be represented using DAGs, showing the joint
relationships between variables. This representation can be used efficiently for defining
joint probability distributions, and possibly drawing conclusions about direct associa-
tions. DAGs can be used to encode conditional independent structures, and generate
convenient factorisations of a joint distribution.
Our naive hope in using DAGs for inference is that directed edges within our DAG
may help to suggest directions of associations. In fact, directions of association can
be very difficult to infer from such DAGs for two main reasons. Firstly, it is very
difficult to be sure that all unobserved confounders have been accounted for in obser-
vational studies and secondly there is the problem of DAG equivalence classes. [39,40]
4.5 Equivalence Classes
Different DAGs can be shown to infer the same underlying 'conditional independence'
model. For example,
37have the same joint distribution. In this case directions of association become indis-
tinguishable. We are interested in the implications of such limitations. Two DAGs are
equivalent if [40]
1. They have the same undirected graph. i.e. same graph but without the direction
of association on it (no arrows); only an indication of association between the
nodes. For example,
is the undirected graph of the previous DAG shown.
AND
2. They have the same v-structures
Consider another example below.
38These DAGs are equivalent because they have the same undirected graph, and the
same v-structure A to C and D to C. It is impossible to tell the direction of associa-
tion between nodes A and B given only this information. Even in a perfect situation
with completely observed population based data, equivalence classes can not be dis-
tinguished.
4.6 Association in DAGs
DAGs are non-parametric models in that they do not imply anything about specific
distributions between the variables. The directed edges between nodes imply a rela-
tionship between variables. If there is no edge then this implies no direct relationship
or association.
There are two main approaches when trying to establish the true underlying model of
a given scenario. Firstly, thinking in terms of directions of association and hypothesis-
ing about these between effect and outcome, then testing this model to see if the data
supports it, or if it can be falsified. On the other hand, assuming that the model is un-
known and trying to use the data to suggest 'likely' models or the most 'likely' model.
In this context, one cycles over all possible DAGs to find the one(s) that best fit(s) the
data. Given an optimal model or set of models we need to consider the correspond-
ing equivalence classes in order to establish information about directionality. Different
equivalence classes may suggest alternative conclusions about the true model. [39]
394.7 Trying to Determine Direction of Association
Essentially, the interest is in trying to analyse which variables have a direct effect on
others. I want to allow for everything that could be related to the variables in question,
e.g. confounders, to make sure the model is correct. In a statistical framework, DAGs
can be used to model all the variables jointly. This will automatically correct for the
effects of all variables included in the model via the edges defined. Therefore, I allow
an algorithm (described later in Section 6) to choose the most appropriate model. A
confounder is a variable which is associated with both the outcome and exposure but
is not on the causal pathway from exposure to disease. Ifthere is a confounder within
the model then this will be automatically corrected for. For example, fitting the model
below
will automatically correct for the effect of confounder C assuming primary interest is
in effect of A on B. The model search algorithm will decide whether the edge between
A and B is necessary when confounder C is taken into account. Note that the DAG
shown above is defined by equivalence class
with arrows in any direction since no v-structures are present. Ifconfounder C is not
observed, or it is not adjusted for in the model, the true effect between A and B is
distorted by the associations of A and B with C.
404.8 Instrumental Variables
Instrumental variables can be used to infer causal relationships.
Consider the following DAG
Figure 4.1: DAG Illustrating Instrumental Variable, B
Suppose we are interested in the association, and direction of association between an
exposure, E and outcome, O. There may be unobserved confounders influencing this
relationship. These are labelled 'U' in Figure 4.1 above.
Here, B is an instrumental variable for the relationship from E to O. A variable is de-
fined as an instrumental variable if it is
1. associated with exposure, E,
2. has no direct effect on the outcome, 0,
3. and does not share common causes with the outcome.
An instrumental variable allows the estimation of the effect of exposure even in the
case of unobserved confounders because it is only associated with outcome if expo-
sure is. In other words, B has an association with 0 but only through E. This approach
may offer a strategy for eliminating or reducing unobserved confounding, in the esti-
mation of E on O.
The instrumental variable forces the direction between E and 0 to be known due to the
v-structures implied by the added node.
41Randomisation of treatment in a randomised control trial, for example, can be consid-
ered an instrumental variable, as shown in the DAG below. It is associated with intake
of a drug (exposure); has no direct effect on outcome due to blinding; and does not
share common causes with outcome due to randomisation.
Genotypes can often be used as instrumental variables in genetic studies. Mendelian
randomisation (MR) states that genotypes are assorted randomly at birth with equal
probabilities. Genotypes are also not influenced by exogenous (environmental) fac-
tors. In this respect, genotype can be used in the same way as a randomised treatment
in a clinical trial by potentially allowing an unbiased estimate of the effects of gene
products (intermediate phenotype) on outcomes (disease risk/status) i.e. as an instru-
mental variable. Genotype can be associated with exposure, have no direct effect on
outcome and does not share common causes with the outcome. The effects of a geno-
type on the outcome in this scenario are assumed to be only through the intermediate
phenotype.
However, it should be noted that genotypes under the assumptions of instrumental vari-
ables through MR have several limitations. This methodology is subject to challenges
such linkage disequilibrium, pleiotropy, weak genetic effects and lack of knowledge of
how genetic variants biologically effect phenotypes. [41,42]
Under MR it may be possible to analyse the effects of an intermediate phenotype on
a disease using genotypes as instrumental variables (IV), in a set up generally free of
confounding by environmental exposures. However, confounding by linkage disequi-
librium (LD) or population stratification may still occur. Population stratification can
be a confounder as different populations carry different risks of disease and genotypes.
Depending on the SNPs typed, the analysis of the genotype effect on outcome may be
42biased due to a possible omission of untyped disease causing variants in LD with the
typed SNPs.
Linkage disequilibrium may also be an issue in that there may be another genotype
in LD with the genotype being used as an IV. This could violate the IV assumption
that the genotype is only associated with disease/outcome through intermediate phe-
notype/exposure as shown in the diagram below.
Figure 4.2: Genotype as Instrumental Variable with Possible Genotype in LD
In the same way pleiotropy may be an issue in using a genotype as an IV. If a gene has
multiple phenotypic traits; or acts via more than one pathway then the effect of this
on the outcome may be confounded by other pathways from gene to outcome. This
would, again, invalidate the assumption that genotype is only associated with disease
through intermediate phenotype.
The association between the intermediate phenotype and on a disease is usually cal-
culated using a ratio of regression coefficients of association between the variables. If
the regression coefficients are as shown in the diagram below
43Figure 4.3: Coefficients of Association
then the expected association between the phenotype and disease is given by
(4.1)
There will be some degree of bias for E(,BPD) when the IV assumptions outlined above
are not met.
If the effect of the genotype on the intermediate phenotype is weak then this wi1llead
to uncertainty in the model. Weak instruments can have underestimated confidence
intervals. A weak correlation between the instrument and error in the original equation
can lead to large inconsistencies. The less precisely the genetic variation predicts the
intermediate phenotype, the less precise the derived effect estimate for the association
between phenotype and disease will be. The above equation equation requires there
to be no large amou~ts of variation in the numerator. A weak effect can therefore vi-
olate the assumptions required of an instrumental variable: an association is required
between the IV (genotype) and exposure (intermediate phenotype). Weak instrument
bias is in the direction of the confounded association between intermediate phenotype
and disease.
There is also the problem of lack of knowledge of how genetic variants have their ef-
fects. This may mean that the pathways modelled are missing variables that would
44affect the estimates or pathways. Genetic variants may all be interacting and it may
not be clear which genotypes to include in the model.
Using genotypes as instrumental variables through Mendelian randomisation should
be done with caution, especially if the gene effect on intermediate phenotype is weak.
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5
BAYESIAN MULTIVARIATE
ADAPTIVE REGRESSION SPLINE
MODELLING
5.1 Aims and Background for SLE dataset analysis
My aim is to investigate Bayesian variable selection methods in regions of high LD. In
particular, to investigate SNPs in the major histocompatibility complex (MHC) region
associated with systematic lupus erythematosus (SLE). Past studies have found several
SNPs in this region to be highly associated with SLE but these SNPs are in high LD.
The major histocompatibility complex (MHC) region on the short arm of chromo-
some 6 was first fully sequenced in 1999 by the MHC Sequencing Consortium. The
gene clusters found to have the most defined functional relevance in terms of antigen
processing and presentation were the HLA class I (HLA-A,-B,-C) and class II (HLA
46-OP,-OQ,-DR). [43] To date more than 100 diseases, including autoimmune diseases,
have been found to be associated with HLA genes, and the MHC region has been found
to have SNPs with the highest associations, in most cases, for autoimmune diseases.
However, there is a large amount of genetic variation and LO across the MHC which
hinders attempts to define the primary signals associated with disease and to determine
primary signals. [44] [45]
Rioux et al [46] aimed to investigate the strong linkage disequilibrium across the MHC
region by genotyping a very large dataset. They aimed to establish the common genetic
variants across the 3.44 Mb region using 10,576 DNA samples. They genotyped 1,472
SNPs, and analysed the genetic associations in this region with several auto-immune
diseases including SLE. Systematic lupus erythematosus (SLE) is a disease of the im-
mune system, and can cause inflammation of the joints, and certain organs of the body.
After initial analysis, Rioux et al [46] pooled the UK and US datasets together as the
individual SNP analysis for association with SLE gave the same 6 top markers using
each dataset. They concluded that their approach was robust, and they had high qual-
ity sample collections. With a pooled dataset, the power of their statistical analysis
increased.
The analysis showed that the top signal for association with SLE was RS 1269852
with an odds ratio of 2.4 and an associated p-value of 5.63E-29. Other top signals
were RS558702, RS3130484, RS3131378 and RS3131379 with p-values of6.75E-29,
1.59E-26, 1.9E-26 and 1.9E-26 respectively; and odds ratios of 2.34, 2.25, 2.24 and
2.24. It was found that these SNPs are all in extremely high LO with RS 1269852 with
r2 > 0.93.
Conditioning on RS1269852 to find secondary associated SNPs, Rioux et al found
RS3135391 to have the highest signal (p-value of 3.9E-06). However, this SNP is also
in high LO with RS 1269852 (r2=0.98). They found signals potentially independent of
RS 1269852 to suggest at least 3 separate signals in this region. The strong LO across
the SNPs found to be associated with SLE makes it difficult to identify the causal ones.
47The aim of my analysis is to use Bayesian variable selection methods to further inves-
tigate the patterns of association across the MHC region.
5.2 Datasets
The data set used for my analysis maps the HLA and non-HLA associations across the
entire major histocompatibility complex (MHC) region. An association study on the
major histocompatibility complex (MHC) region in SLE using data from the Interna-
tional MHC and Autoimmunity Genetics Network (IMAGEN) study, on 1,199 SNPs
from chromosome 6 showed several SNPs with strong evidence of an association. This
is a case-control study with 632 UK SLE cases and 746 UK controls from the 1958
Birth cohort [47]; and 483 US SLE cases and 1049 US controls from the New York
cancer Project. [48]
In order to increase the power of my analysis to detect separate signals of association
with SLE, another dataset was used. The second phase of the IMAGEN study collected
data on Spanish subjects. The Spanish dataset has 5,024 SNPs for 813 individuals in
the MHC region. This consisted of 404 controls and 409 cases. Combining UKIUS
and Spanish datasets together results in a larger dataset with more power for statistical
analysis but raises concerns about heterogenity. There was an intersection of 777 SNPs
between the UKIUS and Spanish datasets.
The plot below shows the distribution of SNPs across the MHC region by dataset. The
imputed dataset is described in Section5.6.
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Figure 5.1: Distribution of SNPs by dataset
The following table summarises the final number of SNPs in each dataset after quality
controlling (detailed in Section 5.3) and the average marker spacing.
Dataset Number ofSNPs Cases Controls Mean Spacing(BP) Median Spacing (BP)
UK/US 1,199 1,115 1,795 6,311 1,864
Spanish 5,024 409 404 1,510 409
Imputed 3,592 1,524 2,199 2,135 687
Table 5.1: Average marker spacing by dataset in basepairs
49Itis clear that the Spanish dataset and the dataset of both UKlUS, Spanish and imputed
SNPs have much finer marker density than the UKIUS dataset (i.e. that used by Rioux
et al). This means with more SNPs, I am more likely to find the primary signals asso-
ciated with SLE.
5.3 Initial Analysis of SLE data
5.3.1 Data Overview
Before quality controlling, the UKIUS dataset contained genotype information for
2,921 individuals on 1,230 SNPs. There were 11people with another family member
in the study as determined by the family identification variable. These were dropped
from my analysis.
For a details on missing SNPs by UKIUS and Spanish data please see Appendix 8.0.1.
There were a maximum of 5% of genotypes missing over anyone SNP and this mini-
mal missing data was imputed using Mach [17]. The imputation methods used by this
program are discussed in 2.7.3. This algorithm uses Estimation Maximisation (EM) to
iteratively estimate the missing haplotype probabilities based on the observed haplo-
types of each individual at other loci. This method should converge to the haplotype
frequencies that equate to the maximum likelihood.
I ran the MACH program for 50 iterations, considering 200 haplotypes at each itera-
tion. This was reasonable for the small amount of missing data [17]. Missing genotype
data was imputed into the UKIUS dataset using information from the UK/US data, and
missing genotype data was imputed into the Spanish dataset using haplotype informa-
tion from the Spanish data. Missing genotypes were imputed as expected values for
each individual.
After imputing the missing genotypes within the UKIUS dataset, 14 SNPs were ex-
cluded from the analysis because they had the same genotype for every individual.
The UKIUS data now contained 2910 individuals with 1216 SNPs. This included 632
50UK cases, 746 UK controls, 483 US cases and 1049 US controls.
5.3.2 Testlng for HWE
I then tested whether or not the SNPs are in Hardy Weinberg Equilibrium (HWE). It
is important that SNPs are in HWE because deviations can be a sign of genotyping
error, inbreeding, population stratification or selection as mentioned in 2.3.1. Devia-
tions from HWE may invalidate assumptions of the analysis and give incorrect results.
Checking for HWE is therefore a necessary data quality check. I used the Pearson
goodness of fit test (also known as the X2 test) to test for deviations in my control data
from HWE. Only the control data is used because if there is an effect of a particular
SNP on SLE, for example, then the genotypes for the cases of that SNP will be out of
HWE by definition. Note: the alternative HWE test using a likelihood ratio method
resulted in the same SNPs being in or out of HWE. Both these tests have 2 degrees of
freedom.
This test using UKIUS controls showed that 17 SNPs were not in HWE with p-values
of less than 10-5• The expected number of SNPs out of HWE in a dataset this size is <
1. These SNPs were not included in my analysis. This left a final dataset for analysis
with 1,199 SNPs.
Doing the same test for each of the 5,024 SNPs of the Spanish controls dataset, showed
that they were all in HWE with a threshold p-value of less than 10-5•
5.3.3 Population Structure
The population structure between the UK and US datasets was tested to ensure that
combining them to form one dataset was sensible. Wrights FST is a measure of het-
erozygosity between different populations and tests whether the allele frequencies by
SNP in each population are comparable. It was developed by Sewall Wright in the
1920s [49,50]. The F-statistic can also be thought of as a measure of correlation be-
tween genes from different populations. The value of the F-statistic is altered by sev-
51eral evolutionary processes, such as mutation, migration, inbreeding, natural selection,
but its primary function is to measure the amount of allelic fixation due to genetic drift.
An F-statistic of 0 indicates no divergence between populations, and an F-statistic of 1
indicates that the populations are completely different.
The F-statistic between UK and US controls was calculated using the R package
polysat [51] to be 0.0006. As described by The International HapMap Consortium [10]
and Holsiner & Weir [52] this value is considered to show that the UK and US datasets
have similar allele frequencies by SNP and so can be merged to form one dataset with
more statistical power for further analyses. Further sensitivity tests to show how analy-
ses changed by UK or US alone will be carried out to illustrate that they obtain similar
results. See Section 5.3.4 below and Appendix 8.2.
The F-statistic between the UKIUS controls and the Spanish controls was calculated
to be 0.005. Although not as close to 0 as the F-statistic between the UK and US
controls, this indicates that the allele frequencies by SNP between the two data sets
are fairly similar, and merging all the data for one statistical analysis is not unreason-
able. [52]
5.3.4 Frequentist test of association
I used a simple frequentist Fisher exact test to initially analyse any SNP associations
with SLE as described in 2.8.1 In this framework, each SNP is tested for an associa-
tion individually. Note: the Bayesian Multivariate Adaptive Regression Spline model
I use later 5.9 has a dominance component for flexibility, and assumes an underly-
ing Gaussian distribution of liability (probit model). However, a Fisher exact test is
asymptotically equivalent to a logistic model so this makes it slightly more difficult for
direct comparisons to be made under the different methods.
52UKIUS Data Analysis
Applying this test to the 1199 SNPs of the UK/US dataset Ifound several to have very
small p-values. The results are shown in the plot below.
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Figure 5.2: Plot of Frequentist p-vaJuesof UK/US SNP Association with SLE
This plot shows that (in order of marker position & in left to right on the plot & high-
lighted by triangles) RS3130484, RS3131379, RS313 J 378, RS558702, RS 1269852,
RS204041O, RS2187668 are highly significant, with frequentist p-values of 7.11E-28,
7.l1E-28, 7. llE-28, 2.06E-30, 4.54E-30, 2.29E-27, 1.29E-27 respectively. Rioux et
al [46] found that RS1269852 had an odds ratio of association with SLE of 2.4 with a
p-value of 5.63E-29. The top two SNPs in the above frequentist analysis; RS558702
and RS 1269852 (Rioux et aI's top SNP) are physically very close to each other (marker
positions 31978304 and 32188]68) and are in high LO (1'2 of 0.961, D' of 0.985)
Testing a large number of SNPs, it is expected that some SNPs would be significant
by chance alone. Therefore in doing genome wide association studies, or in studies
with a large number of variables being tested, it is necessary to change the threshold
p-value from the "normal" value of 0.05 to one of say 5* 10- . This reduces the false
discovery rate of defining too many SNPs to be associated. Using a p-value of 5* 10-8
as a cut off (as used by the Welcome Trust Case Control Consortium (WTCCC) [53]),
53there are 161 SNPs associated with SLE in the above analysis. The dashed line on the
plot represents this cut off.
It is evident from the plot of my simple frequentist analysis that there is a clustered
nature of associations across SNPs on chromosome 6. There is no clear signal as to
which SNPs are actually associated with SLE. This clustering is likely to be largely
due to strong LD within the region and my aim is to disentangle this.
The frequentist p-values from separate UK and US analyses are similar. The top 10
SNPs are the same though in a slightly different order. The top 2 SNPs for the UK
analysis are RS558702 and RS1269852 with respective p-values 5.76E-20 and 1.24E-
19. The top 2 SNPs for the US analysis are RS1269852 and RS558702 with p-values
3.05E-IO and 5.05E-l 0 respectively. These are also the same 2 top SNPs from thejoint
frequentist analysis. In all 3 analyses, the p-values between the top 2 SNPs are very
close. The p-values for the individual analyses are slightly bigger but this is likely to
be due to the smaller sample sizes. This echoes the result of the F-statistic above, and
we can conclude that the datasets are similar enough to combine.
Spanish Data Analysis
Applying the frequentist Fisher exact test as described above to the Spanish dataset, I
found several to be highly associated with SLE. The results are shown inthe plot below.
54Plot of frequentist -10910 p-values of SNP association with SLE
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Figure 5.3: Plot of Frequentist p-values of Spanish SNP Association with SLE
Again, there is a clustered nature of associations across SNPs on chromosome 6. There
is no clear signal as to which SNPs are independent signals associated with SLE. Note
that there is less power in this analysis than in the UK/US one as there is a smaller
sample size (813 individuals vs 2920 individuals).
Using p-values of 5 * 10-8 as a threshold, there is only one SNP associated with
SLE in the Spanish dataset. This SNP is marked as a triangle on the plot above
and is RS9268832 with a p-value of 1.46E-08. However, the plot shows that (in or-
der of marker position and from left to right on the plot), RS3131381, RS3131379,
RS3117574 an RS3 130490 all share a p-value of l.45E-07 and are located very close
to each other and the top ranking SNP on chromosome 6 (marker position numbers
31816442,31829012,31833209,31847099. The top SNP has marker position 32535767)
so it is likely that these are all highly correlated with each other. The next stage was
therefore to investigate the LD between all these SNPs to see if this is the ca e.
Note: the top two SNPs from the Spanish analysis are not in the UKIUS dataset but
the third most highly associated SNP RS3131379 is the fourth highest in the UK/US
dataset. SNP RS3131379 has a p-value of association with SLE in the UKIUS data et
of 7.11 E-28 and 1.45E-07 in the Spanish analysis. The difference in p-values could be
due to significantly less power in the Spanish dataset due to a smaller sample size.
55The top SNP RS558702 from the frequentist UKIUS analysis with a p-value of 2.06E-
30 has a p-value of 3.52E-07 in the Spanish analysis. The second highest SNP from
the UKIUS dataset, RS 1269852, has a p-value of 4.54E-30 in the UKIUS analysis and
4.50E-07 in the Spanish one. These SNPs are ranked 8th and 14th respectively in the
Spanish frequentist analysis.
5.3.5 Linkage Disequilibrium
UK/US Data Analysis
I then investigated the LD between the top ranking 100 SNPs from the UKIUS fre-
quentist analysis. An LD plot created using Haploview [54] [55] shows the levels of
LD between all SNPs selected in order of marker position on chromosome 6 from left
to right. The darker the box connecting the two SNPs, the higher the level of LD be-
tween the two SNPs. The LD value shown in each box is the r2 statistic. The black
boxes drawn on the plot show blocks of LD.
The LD plot of all UKIUS SNPs (in Appendix 8.1) shows that all of these SNPs are
in high LD with several other SNPs. This confirms that the clustering shown in the
frequentist results above is likely to be due to strong LD amongst the SNPs.
The levels of LD between the 10 highest ranking SNPs from the UKIUS frequentist
analysis are shown in the plot below. They are all in LD with at least one other SNP in
the top 10 with r2 > 0.5.
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Figure 5.4: LD Plot of Top 10 UKIUS SNPs from Frequentist Test of Association with
SLE
This shows that the top two SNPs in the above analysis (RS558702 and RS1269852)
are highly correlated with all top SNPs showing an association. The very high correla-
tion between these SNPs could mean that there is only one locus associated with SLE
but it is difficult to establish which one.
Spanish Data Analysis
I then investigated the LD between the top ranking 100 SNPs from the Spani h fre-
quentist analysis. The LD plot (in Appendix 8.1) shows the levels of LD between all.
the SNPs.
To see more clearly, the levels of LD between the 20 highe t ranking SNPs from the
frequentist analysis are shown in the plot below. The top 20 were chosen rather than
the top 10in the UKIUS dataset because the loci in the Spanish data et are more den e.
Ialso wanted to include the two top SNPs from the UK/US for compari on. Again, the
darker the shade of red the box connecting the two SNP , the higher the level of LD.
The top 20 SNPs are all in LD with at least one other SNP with r2 > 0.7 as shown
below.
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SLE
5.4 Intersection of UKIUS and Spanish Data
In order to increase power and the ability to localise the signals of association, the
UKIUS and Spanish datasets were merged. Combining the UK/US datasets and the
Spanish datasets resulted in 772 overlapping SNPs for 3723 individuals; 1,524 cases
and 2,199 controls.
Itwas necessary to flip alleles on 230 SNPs so that those from the Spanish dataset were
on the same strand as those from the UKIUS dataset. Sometimes if the genotyping of
the SNPs are done on different chips e.g. Affymetrix and Illumina, then the major and
minor alleles can be defined differently. This means that Cs are coded a G , or Ts are
coded as As or vice versa. This was the case between the Spanish and UK/US dataset
for 230 SNPs, and so I flipped these strands on the Spanish dataset to match those on
the UKIUS dataset.
There were 34 SNPs with different observed minor allele frequencie. The e were
genotypes coded across both studies as C/G or NT but had different minor alleles. In
order to reconcile this problem, I compared the allele frequencie to those in the Euro-
pean HapMap database and matched the minor allele to this information. [56]
58The dataset merged together of UKIUS and Spanish data was done after imputation for
missing genotypes in the individual datasets but before testing for HWE. Using both
datasets combined, each SNP was tested for HWE in the dataset with more individu-
als. There were 14 SNPs out of HWE (with p-value criteria as in UKIUS and Spanish
analyses) so these were dropped from analysis of the intersection data.
5.4.1 Frequentist Test of Association
Applying a logistic regression test for association and adjusting for population (UK/US
vs Spanish) between each of the 758 SNPs and SLE, several were found to be strongly
associated. The results are shown in the plot below.
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59The plot above shows that the three SNPs with the highest frequentist p-values after
adjusting for population (UKIUS vs Spanish) for an association with SLE (in order
of marker position and from left to right. and marked by triangles) are RS3131379,
RS558702 and RS1269852 with respective p-values of 1.97E-33, 2.73E-35 and 8.34E-
35. The top SNP RS558702 is the top SNP in the UKIUS individual frequentist anal-
ysis (p-value of 2.06E-30), and is the 8th highest in the Spanish analysis (p-value of
3.52E-07). The second most significant SNP RS1269852 ranks 2nd in the UKIUS anal-
ysis (p-value 4.54E-30) and 14th in the Spanish analysis (p-value 4.50E-07). Using a
p-value threshold of a conservative 5* 10-8, there are 124 SNPs in the overlapping
dataset that have an association with SLE.
Again, there is a clustered nature of associations across SNPs and it is not obvious
which SNPs are actually associated with SLE.
5.4.2 Linkage Disequilibrium
The LD plot between the top ranking 100 SNPs from the frequentist analysis is shown
in Appendix 8.1.
The levels of LD between the 10 highest ranking SNPs from the frequentist analysis
are shown in the tables of D' and then r2 below.
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62Considering the plot of frequentist p-values of the overlapping SNP analysis and the
LD between those SNPs with the toplO highest p-values, we may believe that there
could be two underlying causal loci. One represented by the two top hits RS 1269852
and RS558702 which are in extremely high LD (D' = 0.99), and the other repre-
sented by the 4 in the cluster above in the frequentist plot of p-values (RS2239805,
RS3135366, RS2395171 and RS2227139). These 4 SNPs are in very tight LD with
each other (D' > 0.97). This would collaborate with evidence suggested by the single
analyses but gives a slightly more detailed picture.
5.5 Summary of Frequentist Analysis
The table below gives a comparison of the top 10 SNPs from intersection frequentist
analysis with results for the same SNPs in individual UKJUS and Spanish analyses.
Table 5.4: Summary of p-values of Association & HWE p-values by TopSNP & Dataset
Intersection Data UK/US Data Spanish Data
SNPs Association p-val Association p-val Association p-val
(HWE p-val) (HWE p-val) (HWE p-val)
rs558702 3.13E-31 (0.18) 2.06E-30 (0.24) 3.52E-07 (0.35)
rsl269852 8.68E-31 (0.09) 4.54E-30 (0.12) 4.50E-07 (0.36)
rs3131379 3.24E-29 (0.40) 7.11E-28 (0.51) 1.45E-07 (0.35)
rs3134942 4.59E-27 (0.76) 6.37E-26 (0.82) 1.35E-06 (0.16)
rs1150758 5.32E-25 (0.06) 1.09E-24 (0.15) 4.65E-07 (0.70)
rs2071278 2.65E-22 (0.76) 2.16E-22 (0.88) 3.4IE-04 (0.08)
rs2395171 l.lE-20 (0.63) 8.72E-21 (0.69) 1.11E-03 (0.38)
rs2227139 1.64E-20 (0.56) 4.96E-19 (0.63) 1.29E-06 (0.36)
rs3135366 1.64E-20 (0.84) 4.05E-21 (0.91) 3.44E-03 (0.51)
rs2239805 4.S8E-20 (0.21) 6.16E-21 (0.52) 7.89E-03 (0.42)
From this it is clear that the p-values within each dataset analysis are similar. This
63makes it difficult to distinguish the SNPs that are independent signals.
I then carried out simple frequentist tests of association by conditioning on the top
SNPs RS558702 and then RS1269852 in order to examine if there are any indepen-
dent signals within the top 10SNPs from the intersection analysis.
Table 5.5: Table of p-values of Association Conditioning on RS558702
SNPs p-value
rs1269852 0.46
rs3131379 0.18
rs3134942 0.23
rs1150758 0.50
rs2071278 0.66
rs2395171 0.31
rs2227139 6.84E-06
rs3135366 0.33
rs2239805 0.37
Table 5.6: Table of p-values of Association Conditioning on RS 1269852
SNPs p-value
rs3131379 0.62
rs3134942 0.30
rs1150758 0.41
rs2071278 0.80
rs2395 171 0.37
rs2227139 7.78E-06
rs3135366 0.37
rs2239805 0.43
These results show that there are at least two independent signals. It would be more
64efficient to test for an association with all SNPsjointly. This is done in Section 5.9
5.6 Combined Dataset with Untyped SNPs from HapMap
In order to obtain a better coverage of the whole chromosome and therefore to be more
likely to find independent SNPs, untyped genotypes in each dataset were imputed us-
ing information from HapMap (as discussed in Section 2.7.3).
The SNPs missing from each dataset but available in the other, and in HapMap were
imputed in two blocks. Firstly, those missing from the UKIUS but in the Spanish
dataset were imputed using information from the UKIUS dataset and HapMap. Then
those missing from the Spanish dataset were imputed in the same way. This took into
account the fact that the two datasets might have different population structures, and
imputed SNPs into the the Spanish dataset, for example, using information from the
UKIUS dataset would not make sense if they were different. In fact, Wright's FST
between the UKIUS and Spanish datasets for those SNPs in both datasets is 0.005.
This implies that they datasets have similar allele frequencies. The imputed datasets
were combined and an indicator variable was added to determine between UKIUS and
Spanish to allow for different MAFs or effect sizes in the two datasets.
The SNPs used to impute untyped SNPs in each of the datasets were taken from
HapMap. These SNPs were unrelated Utah residents with ancestry from northern and
western Europe. The SNP samples were taken from chromosome 6 within the MHC
region (26000000 to 34000000) for 17individuals each. Mach [17] was again used for
imputation using 50 iterations using information from 200 haplotypes for each SNP
at each iteration. This resulted in a dataset of 3,636 SNPs for 1,524 cases and 2,199
controls. 2,910 individuals from UKIUS (1,795 controls and 1,115 cases) and 813
individuals from the Spanish data (404 controls and 409 cases). I used the expected
genotype value output from Mach so SNPs are now 1.2,0.7, etc., for example. I filtered
any imputed SNPs using r2, which estimates the squared correlation between imputed
and true genotypes. I used a cut-off of 0.8. [56]. This resulted in a dataset for analysis
with 2,733 SNPs.
65The tight LD of the associated genotypes motivates the use of a model search method,
for which Bayesian methods cope better with uncertainty about the model.
5.7 Multivariate Adaptive Regression Splines (MARS)
Multivariate Adaptive Regression Spline (MARS) modelling was developed by Fried-
man [57] to allow for flexible regression of high dimensional data. This model was
motivated by the fact that it can be difficult to approximate the relationship between an
outcome and many variables and we may not know a priori what effect we expect each
variable to have upon the outcome. The set-up of MARS models is described in detail
below.
In a genetic context, a MARS model does not force a specific model for each locus. It
allows different SNPs to have different effects on the outcome of interest. For example,
some SNPs may be dominant while others may be additive or recessive. MARS mod-
els also account for non-linear relationships between outcome and variable, can allow
for interactions, and use variable selection to include the most significant variables in
the model.
5.S Non-linear regression
Sometimes we want to allow for non-linear relationship of the genotypes of a SNP
with an outcome. For example, if we were to fit a linear model to this data.
66Linear Regression of Genotype vs Outcome
Genotype
fj = 1+ 1.5x (5.] )
From the plot, it is clear that this is not a linear relationship. A better fitting model
would be
fj = 1 + l[x - 0]+ + l[x - 1]+ (5.2)
as shown in the plot below. Where [x - 1]+ is known as a basis function, and []+ is the
value of that in the brackets if it is positive; 0 otherwise. For example, [2 - 1]+ = 1
but [2 - 3]+ = O. In the example above, the gradient change at 1. This is known as a
knot.
67Non-Linear Regression of Genotype vs Outcome
Genotype
This is an example of a simple MARS model.
For a single covariate, x, a regression spline model with basis functions for varying
knot points, can be written as
J(
g(X, {3, t, J() = f30 +Lf3,;[x - td~ (5.3)
i=l
where q is a positive integer to denote the order of the spline (e.g. q=2 for a quadratic
spline model; q=l in these examples), as mentioned before []+ is the positive part of
that in the brackets, t1, . , , , i« is a set of candidate knots. Note that for genetic data,
coded as 0, 1 or 2, we only allow knots at values 0, I or 2. To reiterate, knots are points
on the x-axis where the nature of the function changes. All these parameters are es-
timated simultaneously with the regression coefficients f3 and K, the total number of
knots.
As mentioned above, three well known genetic models are the dominant, recessive or
additive model on an outcome. When modelling a disease outcome and we want to
model the probability of disease/ no disease (1 /0) as for SLE outcome, it is desirable
68to work using the probit model on a log scale. This was explained in detail in Section
2.8.2 However, examples of dominant, recessive and additive models are plotted with-
out a log scale for simplicity at this stage.
Effect Under a True Recessive Genotype Effect Under a True Additive Genotype
o o
Genotype Genotype
Effect Under a True Dominant Genotype
o
Genotype
Figure 5.7: Plots of Effects of True Recessive, Dominant and Additive Genotypes
From these plots, it is clear that MARS model is suitable to fit to genotype data, for
flexible models, including those usually fitted, and can allow a different model for each
locus.
The MARS model can be extended to include interaction terms. This can be useful if
for example, genotypes have an interaction effect. For example, if we have an interac-
tion between true additive, dominant and recessive SNP , the effects will look like the
plots below.
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Figure 5.8: Plots of Effects of Interactions Between Genotypes
The MARS model linear predictor for my analysis is written
[(
TJ = f31 +L f3kBk(X)
k=2
(5.4)
where the basis function Bk(X) is
Zj
Bdx) = II[skz(xv(kz) - tkz)l+ (5.5)
z=l
where Zj= lor 2,... depending on number of interactions for that particular basis func-
tion, [.l+ = max(O,.), Z is the degree of interaction of basis function Bi; Skz = -1
or 1 depending on the sign (Note: changing the sign of the basis function can lead to
effects by genotype opposite to those shown on the plots above], v(kz) is a member
of 1,... ,p and indicates the predictor in the model and tl.;z is the associated knot value
with interaction term z for basis function k. Therefore, TJ is a linear combination of
non-linear transformations of the covariates. Let e = {k,fj, z,8,v,i} be a vector of
parameter estimates. In this equation each predictor is constrained to appear only once
in each basis function.
In this analysis for SLE, the MARS model is restricted to have a maximum of 2 inter-
actions.
70Notice that, just as in the case of usual multivariate regression, the effect of each pre-
dictor in the model is adjusted for all other predictors within the model. This should
enable us to tease out the most likely causal loci by automatically correcting for nearby
associated SNPs.
The' Adaptive' part of the MARS model refers to the selection of the optimal model.
The frequentist approach to fitting this MARS model iterates through the possible mod-
els (basis functions), using forward and backward variable selection. As in stepwise
regression, a proposed change in the model is accepted if it results in a significantly
improved residual sum of squares of the fitted model.
In forward selection, the candidate spline term multiplied by the existing basis function
that gives the largest reduction in residual sum of squares is added. In order to reduce
the number of basis functions in the model and to avoid overfitting, a backward dele-
tion is proposed. We can choose which basis functions to delete using the generalised
cross-validation criterion, for example. [58]
715.9 Bayesian Multivariate Adaptive Regression Spline
(BMARS)
It is desirable to search over all "possible" models in order to find those SNPs that
are most important in the prediction of SLE. The BMARS model used should auto-
matically correct for nearby associated SNPs, and only those most directly associated
should be included in the model.
I used a Bayesian Multivariate Adaptive Regression Spline (BMARS) model, devel-
oped by Verzilli et al. [59], to identify the most associated SNPs taking into account
nearby associated SNPs in the data above via Bayesian model averaging.
A Bayesian approach summarises the evidence in favour of model m in terms of the
posterior probability of model m given the data (j(mly). [60]
f(mly) = f(ylm)f(m)
EmEM f(ylm)f(m)
Model averaging refers to averaging over all possible models using either
(5.6)
a)f(fJIY) = f(fJly, m)f(mly) (5.7)
all models m includings
or
b)p(covariate i being in model) = p(mly) (5.8)
all models including covariate i
Verzilli et aI. use a reversible jump algorithm as described in Section 3.7 [34,38]. This
allows the MCMC scheme to sample from any model m for the MARS models con-
sidered. The reversible jump algorithm explores the space of e, proposing to change
the dimension of 0 at each iteration using a birth, death or switch step.
For the MARS models used in this analysis, the acceptance probability of a new basis
function (birth step) is simply [61]
72min {1,BF((/, O)R} (5.9)
where R is the ratio of probabilities (d~;l as described in Section 3.7) and BF«O', 0) is
the Bayes factor (see Section 3.6) of the proposed model (e') compared to the current
model (0).
735.10 Priors for Parameters in the SLE BMARS Model
I follow Verzilli et al. who use similar prior distributions for the parameters e =
{k, {3,z, s, v, t} as Holmes and Denison 2003. Using a Bayesian approach, 0 is treated
as unknown, and all parameters are assigned prior distributions. The prior distribution
on the sign indicator for basis function k, Skz is uniform on {-I, I}, i.e. P(Skz)=U(-
1,1). Predictor variable v(kz) which is used in term z of basis function k and indicates
whether a SNP is included in the model or not, is given a uniform prior p(v(kz))=U(O, ... ,p)
where p is the number of possible SNPs in the model. The knot values tz are uniformly
distributed on the observed genotype values, i.e p(tkz)=U(0,1,2). For the maximum
number of basis functions K that the model is allowed to grow to we set p(K) =
U(I, ... , Kmax), here choosing Kmax=250. The prior distribution for the vector of
spline coefficients, (3, is p({3) = .MV N(O, CT~I). Finally, the prior for CT~is inverse
gamma, i.e. p(CTi2) = gamma(O.01, 1).
The BMARS code was then extended by Verzilli et at. to include a Poisson prior on
the number of variables in the model, as previous code assumed at least one SNP as-
sociated with SLE at each iteration. p(K) '" Pois(A)
A was set to 0.5 as this equates to a very conservative prior of less than one SNP being
included in the model. However, under sensitivity analysis, by varying the values of A,
neither the posterior probability or the number of SNPs being included changed.
In order to simplify sampling from posterior distributions, the probit link function with
data augmentation was used, as explained in Section 2.8.2. The advantage of using
the latent variables Wi. together with conjugate priors, is that posterior sampling of all
parameters is simplified following from the Bayesian linear model, conditioned upon
745.11 Application to SLE association study data
In the SLE dataset, observed values of Y are defined by
u= { ~
if no SLE i.e. control
if have SLE i.e. case
The matrix of x is made up of SNPs, coded as 0,1,2 for the different possible geno-
types as described above in the frequentist analysis; or by expected genotype values in
the case of imputed SNPs.
In every case the prior probability is set so that the expected number of SNPs in
the model is 0.5. Sensitivity of this was examined by altering the mean of the prior
(P(K) '" Pois(>.)) from 0.5 to 10 as this could be a potentially informative prior (see
plot below).
The plot below of probability mass functions of the Poisson distribution with A. = 0.5,
5,10 shows that this could be a potentially informative prior on the number of SNPs in
the model.
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Figure 5.9: Probability Mass Functions of the Poisson Distribution
765.11.1 Analysis of UKIUS dataset
The BMARS MCMC algorithm developed by Verzilli et al. was applied to the UK/US
dataset with 1,199 SNPs for 2,910 individuals. The algorithm was run 10 times for
5,000,000 iterations with a burn-in period of 200,000 with a thin of 800. A large thin-
ning parameter was used to reduce the size of the vector stored in Rover 5 million
iterations. A convergence plot of the posterior probability of the SNP with the high-
est signal shows that only the short burn-in used is required. The model converges at
150,000 iterations but a burn-in period of 200,000 was used to be stringent.
Posterior Probability of AS558702
having an Association with SLE
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Figure 5.10: Cumulative Posterior Probability of RS558702 having an Association with
SLE
The BMARS algorithm was run on the UK and US datasets separately to examine
whether the results would be that different to each other. The posterior probabilities of
each SNP having an association with SLE were similar. See Appendix 8.2
77The BMARS algorithm was run on the combined UKIUS dataset for 5 million itera-
tions with a burn in period of 200,000, and thinning of 800, and repeated 10 times. The
posterior probability of each SNP having an association was estimated by the number
of times the SNP was in the model over all 10 runs divided by 60,000 (the number of
iterations stored). The algorithm was run 10 times in order to check whether there was
any heterogenity between runs. In each case, the posterior probability of each SNP
being included in the model was approximately equal. The posterior probabilities of
each SNP are shown in the plot below.
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Figure 5.11: Posterior Probabilities by SNP of Association with SLE
This plot shows that SNP RS558702 has the highest posterior probability of 0.72 of
having an association with SLE. This was also the top SNP in the UKIUS frequentist
78analysis with a p-value of 2.06E-30. The 2nd ranked SNP in the frequentist analysis,
RS 1269852 (p-value 4.54E-30), has a posterior probability of 0.26. This leads to the
conclusion that RS558702 has the primary association with SLE.
Note: The posterior probability of 0.72 of RS558702 having an association with SLE
does not seem that high compared to a frequentist p-value of association of 2.06E-30.
The weaker Bayesian result could be due to the possibility that there is more than one
SNP effect on SLE and so with a joint analysis, individual effects are smaller as it is
less clear which SNPs have an association. The frequentist p-values are from indepen-
dent tests of association with SLE and do not take into account the joint effects or LD.
Analysing the number of basis functions in the model, when RS558702 is in the model,
we found that there were was a probability of 0.12 of only RS558702 being in the
model, a probability of 0.74 of there being 2 in the model, and probabilities of 0.13 and
0.01 of 3 and 4 basis functions being in the model with RS558702 respectively. From
this we can conclude evidence of a second signal. From the above posterior probability
plot, it is difficult to determine between the levels of signal from RS3135391 (posterior
probability of 0.3) RS 1269852 (posterior probability of 0.26) and RS3135388 (poste-
rior probability of 0.24).
Examining further into which SNPs appear together in each model when any of the top
four SNPs are in the model, I found that RS558702 and RS 1269852 are very rarely in
the model together (probability of 0.0001 of the other being in the model when one is).
When there are two basis functions in the model (posterior probability of 0.73 of that
being the case), RS558702 is in the model with RS3135391 with probability 0.24 or
RS3135388 with probability 0.12. RS 1269852 is in the model with RS3135391 with
probability 0.09 or RS3135388 with probability 0.07.
The prior probability of having 2 basis functions in the model is 0.08.
There do not appear to be interactions of SNPs in the models with the top posterior
probabilities. The probability of RS558702 having an interaction with any other SNP
is 0.05.
79Frequencies (out of the number of iterations with a model using each SNP) for knot
values (i.e. where the gradient of the basis function changes) were plotted for each of
the top SNPs associated with SLE from the BMARS output to show the type of rela-
tionship (dominant, recessive, additive, for example).
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Figure 5.12: Frequencies of Knot Points by Top SNPs
80This plot shows that for the top SNP, RS558702, the relationship with SLE appears to
be additive. The sign of the equation is altered by s, so we are interested in the values
of s against the knots, t (as well as the sign of [3). s is always 1(positive) when the knot
value is 0, and always -1 (negative) when the knot value is 2. It can be either positive
or negative when the knot is at 1. Given the knot value for RS558702 is 2, this results
in the following basis function values at each genotype value
Table 5.7: Basis Function by Genotype (x) for RS558702
x Basis function:[-(x - 2)]+
0 2
1 1
2 0
This leads to a relationship between RS558702 and SLE on the probit scale of (this is
for RS558702 in the model only, with no interactions, and a knot point of 2 which has
a posterior probability of 0.07)
81Effect of RS558702 on SLE on the Problt Scale
Genotype
Figure 5.13: Plot of Relationship of RS558702 on SLE
rt = -0.47 + O.53([-(x - 2)]+) (5.10)
where the parameter estimates are the posterior means given the model.
The model with the highest posterior probability (0.13) involves two basis function
with SNPs RS558702 (.1:1) and RS3135391 (X2) with no interactions. The basis func-
tion involving RS558702 has an s of -J and a knot point (t) of 2. The basis function for
RS3135391 has an s of 1 and a knot point of O. The effect on the probit scale of this
model is
rJ = -0.552 + 0.56([-(Xl - 2)]+) + O.24([(X2 - 0)]+) (5.11)
82A plot of this model looks like
Effect of AS556702 & AS3135391 on SLE on the Probit Scale
o 0
Figure 5.14: Plot of Effect of Most Common Posterior Model on SLE
83Below is a table of posterior probabilities of the most common combination of SNPs.
Note: These model frequencies are irrespective of knots.
Table 5.8: Posterior Probabilities of the Top Models
SNPs in Model Frequency Posterior Probability
RS558702 + RS3135391 8921 0.15
RS558702 + RS3135388 6568 0.11
RS558702 + RS3135352 5032 0.08
RS558702 5017 0.08
RSI269852 + RS3135391 3532 0.06
RS1269852 + RS3135389 2345 0.04
RS558702 + RS396960 2214 0.04
RS1269852 2126 0.04
RS 1269852 + RS3135352 1769 0.03
Note: RS396960 (position 32299558) and RS3135352 (position 32500883) have marginal
posterior probabilities of 0.08 and 0.17 respectively.
84Below are tables of LD measure D' and then r2 of the top SNPs and those included in
the most frequent models.
Table 5.9: D' Between Top SNPs
RS558702 RS3135391 RS3135388 RS1269852 RS396960 RS3135352
RS558702
RS3135391 0.823
RS3135388 0.820 1.000
RS1269852 0.985 0.822 0.820
RS396960 0.953 0.930 0.930 0.953
RS3135352 0.819 0.997 0.997 0.819 0.930
Table 5.10: r2 Between Top SNPs
RS558702 RS3135391 RS3135388 RS1269852 RS396960 RS3135352
RS558702
RS3135391 0.022
RS3135388 0.022 0.996
RS1269852 0.961 0.022 0.022
RS396960 0.053 0.049 0.049 0.052
RS3135352 0.022 0.989 0.993 0.022 0.049
Although, it appears in the plots above that there are 2 clear signals of an association
with SLE (Plot 5.11 and Plot5.8); most likely at RS558702 and RS3135391, the SNPs
in the top models are in high LD. RS558702 and RS 1269852 are in high LD with
85r2=O.96; and RS3135391 and RS3135388 are in high LD with r2=1.
Note: The r2 values indicate less LD between the top SNPs than D'. As described in
Section 2.5 this is a sign that the MAF varies between the SNPs.
In addition, the mean values of f3 for RS558702 and RS1269852 are similar (0.545
and 0.538). The same is true for the mean values of f3 for RS3135391 and RS3135388
(0.245 and 0.247). For plots of posterior densities of f3 coefficients of top SNPs given
they are in the model please see Appendix 8.3. This implies that RS558702 and
RS1269852, and RS3135391 and RS3135388 have similar effects on SLE when in
the model.
However, as the model has not selected between these 2 pairs of SNPs in high LD, it
could be possible that these top SNPs are due to a single underlying untagged locus.
Therefore, I aim to impute untyped SNPs and combine this data with another dataset
to provide more information.
865.11.2 Analysis of Spanish dataset
The BMARS MCMC algorithm described above was applied to the Spanish dataset
with 5,231 SNPs for 813 individuals. The code was run 10 times for 5 million itera-
tions with a burn in period of 500,000, and thinning of 800. The BMARS model of the
Spanish dataset took longer to converge than the analysis of the UK/US dataset. This is
likely to be due to the larger number of SNPs in the Spanish dataset for model selection
(5,231 in the Spanish dataset compared to 1,199 in the UK/US). A convergence plot
of the posterior probability of the SNP with the highest association with SLE is shown
below.
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Figure 5.15: Cumulative Posterior Probability ofRS3129768 having an A ciati nwith
SLE
Note: It appears from this plot that the MCMC algorithm ha not fully onv rged to
a posterior probability of RS3] 29768 having an as ociation with L . How vel', over
every repetition of running the algorithm, the po .terior probability of this a so iation
is the same. The poor convergence is, again, likely t be du to the large number of
87SNPs included in the model.
The posterior probabilities of each SNP are shown in the plot below.
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Figure 5.16: Posterior Probabilities by SNP of Association with SLE
This plot shows that SNP RS3129768 has the highest posterior pr bability of 0.79 of
having an association with SLE. This SNP ha: a frequenti t p-value f 2.1 -06 for an
association with SLE, and was ranked 40th in the frequentist test. This SNP i not in
the UKIUS dataset. The highest signal in the frequentist analy i of the Spani h data
has a posterior probability of 0.02 in the BMARS analysis. The top SNP, RS558702,
from the UKIUS BMARS analysis has a posterior probability of 0.02 in the Spanish
analysis. The differences in the results could be due to th mall sample ize of the
Spanish dataset and the lack of power.
Analysing the number of basis functions in the mod I, when R 312976 i in th
model, we found that there were was a probability of 0.0023 f onJy on ba is fun tion
being in the model (a probability of 0.0003 of RS312976 bing in th m del al ne
88and with no interaction term in the basis function), a probability of 0.66 of there being
2 in the model, and probabilities of 0.28 and 0.05 of 3 and 4 basis functions being
in the model with RS3129768 respectively. From this we can conclude evidence of a
second signal. This result is similar to that found in the UKJUS analysis where there is
a probability of 0.73 of there being 2 signals. There was a probability of 0 of no SNPs
being included in the model.
There were prior probabilities of 0.08,0.013,0.002 of there being 2, 3 or 4 basis func-
tions in the model.
Frequencies for knot values for each iteration of the BMARS algorithm including a ba-
sis function for RS3129768 were plotted to show the genotype's relationship with SLE.
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Figure 5.17: Frequencies of Knot Points for RS312976
This shows that the relationship between RS3129768 and L i additiv a a kn t at
o clearly has the highest posterior probability.
Investigating further into which SNPs appear together in th model with RS3] 29768,
Ifound that the most common model is RS3129768(x) with another ba i function
with interaction between RS1793891(x2) and RS3.115663(x·). This m d I ha p t-
rior probability of 0.05
89'f/ = -0.31 + 0.55([(XI - 0)]+) + 0.60([-(X2 - 2)]+)([(X3 - 0)]+) (5.12)
Below is a table of posterior probabilities of the most common combination of SNPs.
Note: These model frequencies are irrespective of knots.
SNPs in Model Frequency Posterior Probability
RS3129768 + (RS31 15663 * RS 1793891) 2,751 0.05
RS3129768 + (RS2248902 * RS3130070) 1,936 0.03
RS3129768 + (RS3130626 * RS2248902) 1,918 0.03
RS3129768 + RS3130623 1,130 0.02
RS3129768 + RS3131381 1,024 0.02
Table 5.11: Posterior Probabilities of the Top Models
Below are tables of LD measure n' and then r2 of the top SNPs and those included in
the most frequent models.
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92These results, again, show evidence for 2 signals of association with SLE. The differ-
ent SNPs in the top 3 models are in high LD with each other. RS3115663 is in LD with
RS3130070 and RS3130626 with D' of 1. RS 1793891 is in LD with RS2248902 with
D' of 0.997. As with the UKIUS analysis, the model has not selected between these 3
models with 2 basis functions which are in high LD. It could be possible that these top
SNPs are due to a single underlying untagged locus.
For a plot of the posterior density of {3 for RS3129768 given it is in the model, please
see Appendix 8.4
935.11.3 Imputed Dataset Using Hap Map for Untyped SNPs
The BMARS algorithm described above was applied to 2,733 SNPs in this dataset for
3,723 individuals 100 times for 6 million iterations with a burn-in of I million and a
thin of 1,000. Below is a convergence plot of the posterior probability of the highest
signal in the model. For convergence plots of other top SNPs, please see Appendix 8.5.
Posterior Probability of RS558702
having an Association with SLE
20 40 60 80 100
Iteraliona
Figure 5.18: Convergence Plot of Posterior Probability of RS558702 haying an As ocia-
tion with SLE
The posterior probabilities of each SNP having an a sociation with SLE ar shown
below.
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Figure 5.19: Posterior Probabilities by SNP of Association with SLE
This plot shows that yet again the strongest signal of an association with SLE is that
from RS558702 with a posterior probability in this analysis of 0.68. The next high-
est signals (in order from left to right on the plot) are RS 1269852, RS3135391 and
RS3135388 with posterior probabilities of association 0.57,0.34 and 0.32 respectively.
The indicator variable for differences between UKIUS and Spanish subject. had a pos-
terior probability of 1.
The number of basis functions in the model when each of the top SNP are in pr vid
evidence for more than one signal. The table below how the po trior probability f
the number of basis functions in the model when each f th top NP is in th In d I.
95Number of Basis Functions RS558702 RS3135391 RS3135388 RSI269852 Overall
2 0.0004 0 0 0.0007 0.0005
3 0.012 0.006 0.008 0.013 0.012
4 0.25 0.25 0.27 0.27 0.26
5 0.41 0.42 0.42 0.42 0.41
6 0.23 0.23 0.22 0.22 0.23
7 0.08 0.08 0.07 0.07 0.07
8 0.02 0.015 0.01 0.01 0.01
9 0.002 0.002 0.002 0.002 0.002
Table 5.14: Posterior Probability of the Number of Basis Functions in the Model Given
each of the Top SNPs are in the Model
This table shows that there is a posterior probability of 0.4 of there being 5 basis func-
tions in the model. It is therefore likely that there are 4 signals in this data for an
association with SLE. There is a posterior probability of 0.0005 of there only being
one SNP in the model. There was a prior probability of 0.0002 of there being 5 basis
functions in the model.
When SNP RS558702 is in the model there is a posterior probability of 0.0 1of it being
part of an interaction term. When SNPs RS3135391, RS3135388 and RS 1269852 are
in the model, there are a posterior probabilities of 0.04, 0.03 and 0.0 Irespectively of
each SNP being part of an interaction term. There is a posterior probability of 0.99
that the indicator term for difference between UKIUS and Spanish data is part of an
interaction term in the model. The indicator term is interacting with 217 SNPs with
posterior probabilities shown in the plot below.
96Posterior Probabilities of SNP Interacting with Indicator Term
SNPS
Figure 5.20: Posterior Probabilities by SNP of Interaction with Indicator Term
The inclusion of an interaction between a particular SNP with the indicator term im-
plies that there is a difference of the effect of that SNP on SLE between studies. This
difference is being accounted/ adjusted for by the inclusion of the indicator term. How-
ever, the posterior probabilities of the top SNPs being part of an interaction are very
low. Therefore, I can conclude that there is no difference in the effect of the top SNPs
on SLE between datasets.
The posterior probabilities of each SNP specifically interacting with the indicator term
are all very low. Due to the high numbers of ba i function included in mo t of the
models, the posterior probabilities of each specific basis functi n is thinly pread over
a number of models. It is more important to consider the po terior pr bability f each
SNP being in the model at allover all iterations.
Note: If the indicator term was included in the mod lind p nd ntly, then this would
imply that there is a difference between the frequency f cas and ntr I b twe n
the two datasets. In this case, there is a posterior P'' bability of O. 0 f th indi ator
term being included in the model independently. Thi c uld be xplain d by th fact
that 0.38 of individuals are cases in the UK/US dataset compar d t 0.5 in the Ianish
dataset.
97Below is a table of the most common models and their posterior probabilities.
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99The most common model (with specific knot points) has a posterior probability of
0.003. The effect on SLE on the probit scale is
Y = - 0.42 + 0.04(I = Spanish) +0.69[-(Xl - 2)]+
- 0.74[-(X2 - 2)]+ * (1 = Spanish)
+ 0.26[(X3 - 0)]+ + 0.4035[-(X2 - 2)]+[-(X4 - 1.99)J+
- 0.36[-(X5 - 2)]+[(X6 - 1.69)]+
where Xl represents RS558702, X2 is RS3130288, X3 is RS3135391 , X4 is RS6906128,
X5 is RS3132550 and X6 is RS9268220. Note: these SNPs have posterior probabilities
of an association with SLE of 0.67, 0.06, 0.57, 0.01, 0.08 and 0.02 respectively. As
mentioned above, the SNPs spread are more thinly over several model . The posterior
probabilities of individual SNPs over all models is more important.
Frequencies for knot values for each of the top SNPs given it i in the mod J are hown
below to give an indication of their relationship with SLE.
SNP RS558702, no Interaction SNP RS3135301, no Inter.etlon
i__O ;10
SNP AS313S30a, no Interlctlon SNP RS1260052. no Intenctlon
o !O -
e -
Figure 5.21: Frequencie of Knot Points Dr 11p NPs
From this is it evident that RS558702, RS3135391, R 1 5
have an additive effect on SLE.
and RSI269852 all
100The plots below show the posterior densities of f3 given that particular NP i in the
model
Posterior Censity of Beta for RS558702
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Figure 5.22: Posterior Density of /3 As ociated with RS558702
Posterior Density of Beta for RS3135391
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Figure 5.23: Posterior Density of f3 As ociar d with R 31 5.
101Posterior Density of Beta for RS3135388
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Figure 5.24: Posterior Density of f3 Associated with RS3135388
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Figure 5.25: Posterior Den, ity of /3 A. sociated with R 1269852
The mean beta coefficients are 0.57. 0.26, 0.27 and 0.55 f r R 55 702, R 31 5 91,
RS3135388 and RS 1269852 respectiv Iy.
When RS558702 is in the model, there is a po t ri r pr bability fO. 7 fR I 53 1
also being in the model; 0.33 of RS313538 also bing in the model; and 0.000 of
RS 1269852 also being in the model. Similarly, when RS31 5 91 is in th m d I,
there are posterior probabilities of 0.68, 0.002, 0.31 of R 55 702, R I 53 8 r
RS 1269852 also being in the model re p ctively. Wh n R J 5 is in th m d I,
102there are posterior probabilities of 0.67, 0.0008 and 0.32 of RS558702, RS3135391
and RS1269852 also being in the model respectively. Finally, when RS1269852 is
in the model, there are posterior probabilities of 0.001, 0.54 and 0.33 of RS558702,
RS3135391 and RS3135388 also being in the model.
This implies that RS558702 is in the model with either RS3135391 or RS3135388;
or RS1269852 is in the model with either RS3135391 or RS3135388. RS558702
and RS1269852 are rarely in the model together; and RS3135391 and RS3135388
are rarely in the model together.
The tables below show LD measures D' and then r2 for the top SNPs in the imputed
dataset analysis.
The high LD values between RS558702 and RS1269852; and between RS3135391
and RS3135388 re-iterate the point that either is sufficient in the model in each case.
RS558702 RS3135391 RS3135388 RS1269852
RS558702
RS3135391 0.727
RS3135388 0.722 1.000
RS1269852 0.985 0.751 0.747
Table 5.15: D' BetweenTop SNPs
RS558702 RS3135391 RS3135388 RS1269852
RS558702
RS3135391 0.014
RS3135388 0.0138 0.996
RSI269852 0.959 0.0148 0.0146
Table 5.16: r2 Between Top SNPs
1035.12 Conclusions and Discusion
5.12.1 UKIUSAnalysis
It appears that there are 2 causal signals; most likely to be RS558702 and RS3135391.
However, the top 4 SNPs are all in high LD so it is possible these signals are due to
one underlying untagged locus.
5.12.2 Spanish Analysis
There is only one signal in this analysis, namely RS3129768. The top SNPs from the
UKIUS analysis have low posterior probabilities in this analysis. It is interesting that
none of the other SNPs with small p-values from the frequentist analysis have high
posterior probabilities. It is especially interesting that RS558702 or RS 1269852 or any
SNP in a similar position on the chromosome in high LD do not come up.
A simple frequentist generalised linear model to investigate the relationship between
SLE and RS3129768 and the top 4 SNPs from the UK/US analysis, showed that the
best fitting model was that with both RS558702 and RS3129768. In fact, the p-value
for RS3129768 was more significant when conditioning on RS558702.
However, the convergence plots 5.15 show that the model has not converged properly.
This could be due to the number of possible SNPs in the data to select from. The
BMARS model can not cope with such a large dataset, especially with only 813 indi-
viduals.
In addition, the top SNP, RS3129768, from the Spanish dataset is only in LD with
one other SNP in the SNPs with p-values < 10-05 from the frequentist analysis. The
top SNP from the UKIUS and combined analyses, RS558702, on the other hand is in
high LD (r2 >0.8) with 25 other top SNPs from the frequentist analysis. This includes
RS 129852 which is second ranking SNP from both the UKIUS and combined analyses.
The other signal found in the UKIUS analysis was either RS3135391 or RS3135388.
These SNPs are in high LD with 4 other SNPs ranking highly from the frequentist
104analysis.
The total posterior probabilities of all SNPs in LD (r2 >0.8) with RS558702 is 0.51
i.e. there is a posterior probability of 0.51 that at least one of these SNPs is associated
with SLE. This high posterior probability spread across several SNPs indicates that the
model appears to be splitting the selection of particular signals between SNPs which
are in high LD. It is possible that RS31269852 is selected as it is not in LD with any
other SNPs that have a frequentist effect with SLE but it, itself does.
5.12.3 Analysis on Combined UKIUS and Spanish Dataset
There are again. two main signals in this analysis. RS558702 with either RS3135391
or RS3135388; or RS 1269852 with either RS3135391 or RS3135388. These are the
same top 4 SNPs from the UKIUS analysis. However. the top SNP from the Spanish
analysis (RS3129768) is not included in the imputed dataset analysis as it was not in
the UK/US dataset or in HapMap for imputation purposes.
If RS3129768 is removed from the Spanish BMARS analysis. then another signal
(RS9271775) has a posterior probability of 0.8 and is again the only signal. RS9271775
is in high LD with RS3129768. This SNP, however, is in the imputed dataset but has a
very low posterior probability. as shown in the table below.
105Table S.17: Table of Posterior Probabilities in Imputed Data Analysis of SNPs in High
LD CD' of 1)with RS3129768 in Spanish Dataset
D' r2 Position RS number Posterior Probability
1 0.003 31647414 RS2516312 6.80E-05
1 0.018 32762692 RS9275 184 0.00048
1 0.011 32674134 RSI1754183 0.000178
1 0.019 32776824 RS9275383 0.000248
1 0.004 32911977 RS9378275 0.00015
1 0.004 32025270 RS2072634 0.000104
1 0.010 32038330 RS2734331 6.60E-05
1 0.Dl8 32790115 RS3957148 0.000188
1 0.012 32904771 RS4148876 4.80E-05
1 0.009 31255073 RS9263823 0.000826
1 0.002 32232402 RSI0947233 0.00016
1 0.009 32475975 RS3817964 0.000102
1 0.819 32702306 RS9271775 0.000152
1 0.029 32492505 RS9268541 0.001178
1 0.006 30046004 RS6457116 0.00012
1 0.017 32792235 RS9275614 8.40E-05
1 0.017 32793528 RS3916765 9.20E-05
1 0.027 31752619 RS13295 0.000328
1 0.029 32523953 RS13209234 0.000568
1 0.017 32789997 RS3998159 0.000358
RS9271775 is the best best predictor of RS3129786(with r2=0.81 and D'= 1) but it
has a very low posterior probability of association with SLE in the imputed dataset
analysis of 1.00E-04. From this, it is possible to conclude that given the higher power
of the combined dataset and conditioning on RS558702, RS 1269852, RS3135391 and
RS3135388, the top SNP from the Spanish analysis does not have a high posterior
probability of association with SLE. The Spanish dataset only has 813 individuals so
it makes sense that these results, together with the conclusions above, on their own are
not as convincing.
The results show that there are 5 basis functions in the model with posterior probability
0.42. This indicates that there are 5 signals in the data. It could be that there are more
106underlying untyped causal SNPs along the chromosome. Rioux et al [46] concluded
that there were two signals; RS1269852 and RS3135391. This study has shown that
RS558702 has a higher posterior probability than RS 1269852 but is also likely to be
one of 2 signals with RS3135391. It has also highlighted that there may be 5 signals
in the MHC region.
My BMARS model provides an automatic way of dealing with interactions and non-
additive genotypic effects on SLE. BMARS does not assume a particular model and
allows the data to select the SNPs with the highest posterior probabilities of associa-
tion. It is a convenient and quick method for multivariate Bayesian model selection. It
took less than 1 hour to run the BMARS analysis for 6 million iterations on a dataset
with 2,733 SNPs for 3,723 individuals.
In a frequentist framework, tests of association could be carried out conditional on the
top signals found in the SNP by SNP tests of association. However, there are more
than 100 SNPs in the dataset with p-values of association < 5 * 10-8• A step-wise
regression model may lead to different results each time and not be time effective.
Under a Bayesian framework, uncertainty is quantified as the results give the probabil-
ity a particular SNP has of being in the model.
In conclusion, I think BMARS is useful for datasets with :5 3,000 SNPs. (With more
than 3,000 SNPs in high LO, the model has difficulty in selecting the true SNPs asso-
ciated with SLE.) It selects the most important SNPs, gives a clear indication of the
number of signals in the data and runs quickly. Finally, it is a relatively straight for-
ward way of allowing for interactions and the possibility for different effects of each
SNP.
107CHAPTER
6
BAYESIAN NETWORKS FOR
GENETIC ASSOCIATION STUDIES
6.1 Aims and Background
Genetic association studies have great potential to dissect the genetic basis of dis-
ease but raise a number of challenging and interesting statistical questions. These
include both the potential complexity of the disease state, which may be categorised
by a number of response variables, and the need to cope with large numbers of poten-
tial explanatory variables, both genetic and environmental. There are also complicated
relationships between intermediate phenotypes or biomarkers; and genes and disease.
Questions regarding how these are modelled jointly are important.
Coronary heart disease (CHD) is one of many diseases that results from complicated
interactions between genetic and environmental factors. This means that identifying
the genetic and environmental causal factors and understanding the relationship be-
tween disease and biomarker/intermediate traits is very difficult. By 1981, already
108over 200 phenotypes had been shown to be associated with a higher risk of CHD [62].
I am interested in modelling the pathways between genotypes associated with CHD
and a number of these phenotypes.
This study was particularly motivated by the work of Drenos et al [63]. They inves-
tigated the associations of genotypes with multiple blood biomarkers linked to CHD
risk. It has been shown previously that the blood biomarkers associated with CHD are
highly correlated with each other.
Changes in biomarkers such as lipid and lipoprotein particles and proteins involved in
inflammation and coagulation, have a tendency to group amongst those patients with a
higher risk of CHD. This makes it difficult to determine the relationships and direction
of these relationships with CHD. Due to the correlation amongst these biomarkers,
establishing an independent effect on CHD outcome is hard. The associations found
between the blood phenotypes and CHD could be causal. However, it could be that
reverse causation or confounding is present.
It has been shown that several candidate gene and genome wide association stud-
ies [64-66] that nearly all these highly correlated biomarkers associated with CHD are
also associated with SNPs. Drenos et al examined several SNPs associated with CHD,
and found that these SNPs also had relationships with several blood phenotypes. From
their findings, Drenos et al propose that information on genotype and blood pheno-
types may be used to disentangle the complicated relationships with disease outcome.
As discussed in 4.8, due to Mendelian randomisation, genotype allocation is consid-
ered to be randomly assorted. It is therefore possible to use these genotypes as possible
instrumental variables in analysing the complicated associations and directions of re-
lationships between these biomarkers. Consequently, associations between CHD and
genotype; and blood phenotype and genotype should not be subject to the problems of
confounding because genotypes do not vary due to phenotype, disease or any exoge-
nous factors.
The analysis done by Drenos et al is limited in that only univariate associations be-
109tween the genotypes, phenotypes and disease outcome are highlighted. I aim to de-
velop methods for the joint analysis several phenotypes and genotypes using directed
acyclic graphs (DAGs). Joint analyses of all this information could be used to disen-
tangle CHD pathways amenable for possible treatment. DAGs allow us to model data
jointly and therefore correct for other variables within the model. This allows us to
get a better understanding of the underlying structure of the data and possibly untangle
correlated factors. I aim to use these methods for modelling intermediate phenotypes
and disease outcomes to better understand thejoint relationships between them.
The relationships I will focus on are between APOE, CETP and APOB genotypes; and
HDL- and LDL- cholesterol, triglycerides, C-reactive protein, and apolipoproteins A
and B after these were highlighted by Drenos et al.
6.2 NPHS-II Data
The Northwick Park Heart Study II (NPHS-II) on coronary heart diseases is a prospec-
tive study of 3012 healthy middle-aged men aged 50-64 years at recruitment, sampled
from nine UK general practices between 1989 and 1994. Measures were made of
at least 15 circulating blood factors associated with CHD risk that included both cir-
culating proteins, and non-protein metabolites. By December 2005, after a median
follow-up of 13.6 years, there had been 296 definite fatal or non-fatal CHD events
(230 in 2401 of the genotyped sample. [63]
The table and plot below summarise the relationships found by Drenos et al.
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Figure 6.2: Association between SNPs and phenotypes of men from NPHS [63]
Figure 6.1 shows the relationships between phenotype measures and it is apparent that
they are correlated with each other. Figure 6.2 highlights the relationships between
SNPs and phenotypes of men in the NPHS. It is obvious that the phenotypes are as-
sociated with more than one genotype, and several are associated with the same geno-
types. For example, APOE genotype is associated with both eRP level and APOB
level. These relationships, and other subsets, will be discussed later in Section 6.4.
I will investigate how these relationships work jointly. Much is known about biological
associations for coronary heart disease between certain genes and phenotypes, and so
certain results can be expected. If these results are not found then it may be an indica-
tor that the proposed algorithm is ineffective of selecting the "correct" model, and so
these data are perfect for initial testing purposes as well as further explanation.
112The plot below shows the number of missing genotypes in my data by individual.
Those with >30% missing genotypes were deleted which left a dataset of 2,385 indi-
viduals.
Histogram 01 Missing Genotypes by Individual
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Figure 6.3: Histogram of number of missing genotypes by individual
Once those with >30% missing genotypes were deleted, the number of mi sing indi-
viduals by genotypes were as described in the table below. Th table gives a summary
of the the variables used in my PhD from the NPHS-II.
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114APOE is defined as a two SNP variant: rs429358 + rs7412. It is known that these
two SNPs work biologically together. [67] Together they are commonly known as the
APOE 'genotype', and is how they will be referred to from now in this PhD. For the
other genotypes in my analysis, I used one SNP per gene and these are summarised
below.
I Genotype I RS number
LPL rs264
CETP rs708272
APOA r86589566
CRP rs3091244
APOE rs429358+rs7412
APOB rs585967
The tables below show the LD measures between the genotypes used in my analysis;
firstly D' and then r2. Itis clear that these genotypes are not correlated with each other.
LPL CETP APOA CRP APOE APOB
LPL
CETP 0.016
APOA 0.174 0.058
CRP 0.016 0.081 0.277
APOE 0.0371 0.066 0.300 0.019
APOB 0.030 0.051 0.014 0.111 0.105
115LPL CETP APOA CRP APOE APOB
LPL
CETP 3.45e-05
APOA 4.02e-04 1.98e-04
CRP 8.55e-OS 3.07e-04 3.41e-04
APOE 1.04e-03 1.31e-03 1.Sge-03 9.S3e-OS
APOB 2.6ge-05 3.S6e-04 8.60e-OS 1.28e-04 4.51e-04
6.3 Methods
I expanded methodology proposed by Fronk and Giudici [68] for Markov Chain Monte
Carlo (MCMC) selection for directed acyclic graphs (DAGs). Fronk and Giudici pro-
pose methods to cycle over possible DAGs searching for the relationships with the
highest posterior probabilities between nodes, using an MCMC with reversible jump,
developed by Green [34]. I expand their methodology to a genetic context, and to allow
for specific issues relating to modelling complex disease pathways between genotypes,
intermediate phenotypes and disease.
6.3.1 Directed Acyclic Graphs
In this framework, the DAG (see Chapter 4 for clarification) is set up so that each node
is a variable; a genotype or phenotype. An arrow between them indicates a direct as-
sociation between them, which or or may not be informative about the direction of that
association. The joint model of all data will automatically correct for the effects of
all variables in the model via the edges defined. This model allows us to distinguish
between direct and indirect effects as well as explore possible directionality of rela-
tionships. Since different DAGs can belong to the same equivalence class (see Section
4.S), directions of association may become indistinguishable and I am interested in the
implications of this. Note that in this model a genotype can not be dependent on a
phenotype as this does not make biological sense. A genotype can not be determined
by levels of phenotype.
116The joint model of all the data will automatically correct for all the effects of all vari-
ables included in the model via the edges defined. Therefore if I allow the algorithm
to choose the most appropriate model any confounders included in the model will be
automatically corrected for.
6.3.2 Algorithm Overview
A brief overview of the algorithm proposed is outlined below. This is then explained
in more detail.
• Start at any (legal) DAG model.
• Propose a directed arrow between two variables.
• When an association is already included in the model, check that addition or
reversal of proposed arrow to current DAG does not lead to a cyclic graph, and
that direction of arrow makes sense. Note: As discussed above, a genotype can
not be dependent on a phenotype.
• Reversible jump MCMC; select birth, death or switch step at each iteration de-
pendent on current DAG and directed arrow proposed.
• Accept or reject proposed change in arrow between two variables.
• Gibbs sampler, based upon current DAG, to update model parameters.
• Iterate until convergence.
• Analyse DAGs with highest posterior probabilities.
6.3.3 Bayesian Multivariate Gaussian Linear Regression
Given the current DAG, d, and following methodology developed by Fronk & Giu-
dici [68], I jointly consider a Gaussian regression model for each phenotype Xi re-
gressed upon it's parents (genotype or phenotype) for i=1,... ,p, where p is the number
of nodes in the model. The number of parents, pa(i), varies by node and the set of
117parents for node Xi is denoted by matrix Xpa(i) with dimension n x Pi. n is the number
of individuals in the dataset. Each regression model is defined as:
where {3io is the intercept term, (3il are the regression coefficients, pa(i) indicates the
parents of node Xi and aT is the partial variance of Xi given parents pa(i).
The priors for (3, a and d are given by:
p(d) = ~
where D is the total number of possible DAGs, given the number of nodes Xi. This is
discussed more below in Section 6.3.5. I is the identity matrix with a dimension of the
number of parents + 1 for the intercept term. This assures the coefficients of this re-
gression model to be mutually independent, a priori. (J is given an inverse gamma prior
for computational simplicity as this is the conjugate (see Section 3.3) for the variance
of a Gaussian prior.
Again. as in Fronk & Giudici. using the factorisation and global parameter indepen-
dence properties of joint distributions (for details see [69]), the joint distribution is
given by
118(6.1)
6.3.4 Matrix of AllowedDirection
As mentioned previously, it is not possible for a genotype to be a child as it cannot be
determined by phenotype level or disease status. It is also assumed for this analysis in
particular that the genotypes do not have any association with any other genotype as
they are not in LD. Therefore, the DAG model search space needs to be limited in my
algorithm to account for this. i.e. there can never be an arrow from a phenotype node
into a genotype one, or any arrows between genotypes.
After proposing an arrow between two nodes at each iteration, it is checked that the
proposed association and dependency makes sense. If not, then another arrow will be
proposed until it does. This is done using a p*p matrix of Os and 1s (where p is the
number of nodes) was developed. The ith row and the jth column is 0 if a move from
parent i to child j is not allowed, and 1 otherwise. The Os and 1s are dependent on
whether the ith row and jth column indicate a directed association between a genotype
and phenotype, or between phenotypes.
6.3.5 Testfor Acyclicity
At each iteration, the proposition of a new arrow must also be tested to check whether
its addition to the current DAG model will create a cycle.
119A graph is acyclic if it contains no cycles. i.e. there are no closed loops.
The proposed DAG will not be acyclic if and only if one of the following steps is true
1. one of the parents of the new proposed parent is the child proposed
2. one of the grand-parents of the new proposed parent is the child proposed
3. one of the great grand-parents of the new proposed parent is the child proposed
4. etc. depending on how many nodes could be included in a possible loop. i.e.
there is a maximum of (p-I) possible generations
If the arrow fails this check, then another is proposed until I am proposing a new di-
rected acyclic graph.
Prior on DAGs
Under the framework used by Fronk and Giudici, the prior on each DAG, d, is 1:5 where
D is the total number of possible DAGs, given the number of possible nodes Xi in the
model. In this case, each possible DAG is selected with equal probability.
A new arrow is proposed randomly with equal probability. Fronk and Giudici have
no restrictions on the relationships on the relationships between nodes: each possible
DAG with the addition of a new arrow proposed is allowed. However, given the re-
stricted direction of association from a genotype to a phenotype in my proposed model,
it is not clear whether each possible DAG has an equal probability a priori of being se-
lected. Given the prior of equal probability for every possible arrow given restrictions,
I investigated whether the model would favour 'mid-size' DAGs.
In order to investigate if this would favour any DAG model in particular, I ran a MCMC
algorithm for 6 nodes with no likelihood function, data or priors on other model pa-
rameters. The model used was to propose iteratively an arrow between two. nodes
120uniformly at random.
All proposed steps were accepted with probability 1. The results gave probabilities of
selecting each possible DAG and numbers of arrows included at each iteration. Below
is a histogram of the number of arrows in the model over 200,000 iterations.
Histogram of Number of Arrows In the Model
nn nn
10 12
Numbor of Arrows
Figure 6.4: Histogram of number of arrows in D under prior of uniformly selected arrows
This shows that under the prior of equal weight to each possible arrow at each itera-
tion, there is a prior probability of 0.17 of 5 arrows, 0.22 of 6 arrow, and 0.22 of 7
arrows out of a maximum of 12 in this particular model with 6 nodes and 3 genotypes.
Therefore, this prior favours 'mid-size' DAGs. This will be taken into consideration in
analysis of the results.
6.3.6 Application Using Reversible Jump MCMC
I wish to estimate posterior probability p(d,,B,cr2Ix) and the marginal distributions
p(dlx), p(,Blx) and p(cr
2Ix).
121Again, following the methodology outlined by Fronk and Giudici, I use reversible
jump MeMe to sample from the joint posterior distribution of d, !3and a in order to
make inference about these parameters; in particular to discover the most likely mod-
els underlying the data (i.e. d with highest posterior probability). My aim is to cycle
over possible DAGs to find those with the highest posterior probabilities. As described
in Section 3.7, a reversible jump algorithm allows sampling over models with varying
dimension, as is the case with my DAG model space.
To re-iterate, at each iteration, arrows are randomly proposed to be added, dropped or
direction swapped. In a 'birth' step a new arrow is added to the model; in a 'death' step
an arrow is dropped from the model; and in a 'switch' step the direction of association
between two nodes is reversed. In my algorithm, a child j, and parent i, are randomly
selected, testing for acyclicity where necessary to make sure such a move would not
produce a non-acyclic DAG. If child j already has i as a parent then it is proposed to
drop the association between i andj, and remove node i as a parent of j (a death step).
Ifchild j doesn't have i as a parent, then it is proposed to add an association from i to
j, and add node i to the model for child j (a birth step). However, if i has j as a parent,
then it is proposed to swap the direction of association between the two nodes so that i
becomes the parent, and the model for node i gains a parent, whilst the model for node
j loses a parent.
If a birth step is proposed, then a new coefficient for the association of i being a
parent of j is introduced, (3;j' The proposal distribution of the new coefficient is
q((3;j) f'oJ N(O, 1]2). The acceptance probability of this step is reduced to:
b _. (1 p(Xj Ixpa' e» !3jlpa' e» o-;Ipa' (j»p(!3jlpa' (j) IO;lpa'(j» ) (62)
pro accept - mzn , , 2 2'
q(f3ji)p(Xj IXpa(j) , !3jlpa(j), 0jlpa(j»p(!3jlpa(j) IOjlpa(j»
where xpa'(j) refers to the proposed (new) matrix of parents j for child i i.e. this ma-
trix has increased in dimension by 1, !3jlpa'(j) refers to the proposed (new) matrix of
{3swhich now includes another (3 for the extra parent of i, and similarly for o;lpa' (j)'
2 2 .. . . p(O';Jpa' (j)Id)p(d)
0jlpa'(j) = 0jlpa(j) and p(d) IS uniform so there IS no need to include the p(O:jlpa(j)ld)p(d)
122part of the acceptance ratio as it cancels out.
Ifthe step is not accepted then the DAG remains the same for this iteration. If a death
step is proposed, then the acceptance probability is essentially the reciprocal of that for
the birth step, and I propose to drop the coefficient flij relating to the directed associa-
tion from i to j.
If a switch step is proposed then, iloses j as a parent, but j gains ias a parent. There-
fore, I lose the regression coefficient flji from flilpa(i), but I gain fl;j to the vector fljlpa(j)'
The proposal distributions, then, are those proposed by Gelman (1995):
(6.4)
where V' = (X;a/(i)Xpal(i))-l. The proposal distributions for {3~lpal(j) and (7~~pal(j)are
derived similarly. Fronk and Giudici suggest that these proposal distributions are used
to achieve high acceptance rates by proposing to assign new values for all parameters
associated with i and j at a specific iteration. The parameters are drawn from the cur-
rent model. The acceptance probability of this step is:
prob accept
(6.5)
123where the 's indicate matrices or vectors with dimensions of model proposing. For
example, Xpa' (i) relates to the matrix of parents of i, including a column for proposed
child j as a result of the proposed switch step.
The final step of the algorithm is to update the regression coefficients, and their vari-
ance with the new vectors ,B;lpa(i) and (T~pa(i) using the Gibbs sampler based upon their
full conditional distributions:
(6.6)
(6.7)
where Oi/ull = oilpa(i) + O.5(n +p) and
Ai/ull = Ailpa(i) +O.5( (Xi- Xpa(i),Bilpa(j»)T (Xi- Xpa(i),Bilpa(i) )+(,Bilpa(i) -bi1pa(i»)T(,Bilpa(i)-
bi1pa(i») )
6.3.7 MissingData
Missing genotypes were imputed using Mach [17]. I ran the MACH program for 50
iterations, considering 200 haplotypes at each iteration. This was reasonable for the
small amount of missing data, as shown in the histogram above 6.3. Each of these had
a minimum r2 of 0.9. r2 estimates the squared correlation between imputed and true
genotypes. I used the expected genotype value for each missing genotype.
I assume the missing data to be missing at random (MAR) [70]. The missing phenotype
data was imputed using a Gibbs sampler within the above algorithm. At each iteration,
the missing data was sampled using the conditional distribution of the missing data at
a specific node given current values of all parents, children and related parameters of
the current DAG. Consider the example of a DAG below to illustrate the joint model
124to be considered when sampling the missing values of x. ihas two parents pa(i)l and
pa(ih. two children jl and j2 with parents other than i ml and m2; and m3 respectively.
Denoting Ximi .. as the vector of missing phenotypes of Xi for each node i= I•...• p. the
number of nodes in the DAG at each particular iteration. and the notation used above.
the conditional distribution is given by
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-.0 --127where Xi is the phenotype I am imputing missing values for, xpa(i)mi .. is the matrix of
parents of i corresponding to the missing values of Xi, similarly xpa(j)m ... represents
the column relating to i as a parent of j of the matrix of all parents of j; and specifi-
cally the elements of that column associated with the missing elements of Xi, Xlimi ..
represents each element of missing phenotype Xim ••• for 1 = 1, ... , ni,ni .. , f3iO is the
13 coefficient associated with the intercept value of f3ilpa(i). Xljmi .. represents each el-
ement of Xj (where j is a child of i) corresponding to missing phenotype Xim ... for
l = 1, ... ,nimi •• , f3jO is the (3 coefficient associated with the intercept value of f3jlpa(j),
{3jm is the vector of {3sassociated with parents of j other than i, Xlmm ... represents
each element of Xm (where m is a parent of j not equal to i) corresponding to missing
phenotype Xim ... for i= 1, ... ,nimi •••
This equates to a Gaussian distribution for Ximi •• , and each missing value of each node
i is sampled from:
(
13ilpa(i):Cpa(i)miu + " . 13j~a(j)(i) (x. _ 13.. -" r.l . X .) )
N O}lp4(i) L....;J O";lpa(j) Jmi"(') ]0 L....;m fJm(}) m(J) 1
1 '1 ,,13j lpa(j)(i)
1 '" /3; [paUj(i) =r- + L....;. 2
;;Z-+L.,j ,,2 O"ilpa(i) J O"jlpa(j)
ilpa(') jlpa(j)
(6.10)
6.3.8 Binarydata
The algorithm was then extended to allow for binary phenotype data. Via data aug-
mentation I can model binary regression with a probit link, using essentially a Gaus-
sian linear model. [25,71].
As with the data augmentation in binary probit regression in the BMARS chapter, con-
sider
(6.11)
where Xi is a binary phenotype. Note: Xi can be either a proposed child or parent here.
128Introducing a set of latent variables Zi for the ith observation where
(6.12)
such that
1 ifzi>O
o otherwise
In the case of my algorithm, at each iteration, z was sampled from a truncated Gaus-
sian distribution with mean of expected value of each element given the distribution of
the current DAG. i.e. the mean value given current values of all parents, children and
related parameters of current DAG for each binary node. Taking into account the joint
distribution of the current DAG model
(6.13)
using the same principle as for missing phenotype data.
So I sample Zi from a truncated Gaussian distribution defined by
(6.14)
1296.4 Assessing Performance of the Algorithm
The algorithm was run for several different numbers of nodes, using simulated data
at first to check the algorithm was working correctly, and then using data from the
NPHS-II study from which I selected variables which already had known biological
associations to further test the algorithm.
6.4.1 Simulationstudy
The first step of testing the algorithm, was to use simulated data. I used up to 6 nodes
with up to two simulated genotypes, and up to 5 simulated phenotypes for 1,000 in-
dividuals. The genotype was simulated by randomly sampling the number 0,1, or 2
1,000 times to correspond to the 3 possible genotypes with probabilities under HWE
with MAF 2:: 0.05. For my first simulation with 3 nodes, the phenotypes were simu-
lated by setting
phenotype! = 0.7 + (2*genotype) + (Xl
phenotype2 = 0.5 + (1.5*genotype) + (2.5 * phenotype l) + Q2
where (Xl and Q2 '" N(O, 1). Note: These simulated effect sizes are large in compari-
son to the small genotypic effects expected on phenotypes.
The chains converged quickly within 100 iterations, and settled down between the two
DAGs of the same equivalence class within 2000 iterations. The posterior probabilities
of the resulting DAGs showed that associations between the nodes were exactly as ex-
pected. The results gave the following DAGs and posterior probabilities (after bum-in
period):
130Posterior probability of 0.41 Posterior probability of 0.37
The two DAGs above are in the same equivalence classes and have approximately
equal posterior probabilities of 0.41 and 0.37. The marginal posterior probability of
a direct association from phenotype 1 to phenotype 2 is approximately equal to that
from phenotype 2 to phenotype 1(~0.5). In addition, the regression coefficients were
very close to the true values simulated. The first DAG has a model of
phenotypel = 0.70 + (2.01*genotype)
phenotype2 = 0.50+ (l.47*genotype) + (2.51 * phenotypel)
6.4.2 Checks for convergence
Checks for convergence were done in R using the coda package [72], for all coeffi-
cients of directed associations for each node. Convergence plots, and summaries of the
coefficients were produced and shown below.
Auto-correlation plots below show that the algorithm is mixing well and there is no
dependence between iterations after a lag of 10.
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Density plots of the first 10,000 iterations of each coefficient specific to the DAG sim-
ulated show that the model has recovered the coefficients as simulated in each case.
(0.7,2,0.5, 1.5 and 2 respectively).
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132Trace plots of the first 10,000 iterations of each coefficient specific to the DAG simu-
lated show that the model has converged.
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I simulated data for more nodes and was able to recover the true tru tur s. I simulated
for up to 6 nodes with 2 million iterations.
For example, I simulated 3 phenotypes with the following relation. hips to the geno-
type simulated as above. The use of genotype 2 a. an instrum ntal variable (see ection
4.8) should allow me to discover the direction of th arr w b tween ph notype I and
phenotype2 as this will lead to a model with a DAG in it own unique quival 11 e clas .
phenotype] = 0.7+(2*genotypel) + (1.S*genotype2) + 1
133phenotype2 = 0.5 +(1.5*genotypel)+ (2.5*phenotypel)+ a2
where al and a2 rv N(O, 1).
I ran the algorithm for 1,000,000 iterations with a bum-in period of 100,000 and a
thin of 100. The results gave the following DAG (showing exactly what was modelled
above) with posterior probability 0.92.
The same convergence plots as for the 3 nodes simulation above showed that the al-
gorithm mixed well, the true correlation coefficients were recovered and the algorithm
had converged after 50,000 iterations. As there is no DAG equivalent to this one, the
direction of association (as that simulated) between phenotype 1 and phenotype 2 is
clear due to the addition of genotype 2 as an instrumental variable.
In addition, a table of the marginal probabilities of each arrow shows that the algorithm
selects a directed association from genotype 1 to phenotypes 1 and 2 with posterior
probability I, from genotype 2 to phenotype 1with probability I, from genotype 2 to
phenotype 2 with probability 0.09, and from phenotype 1 to phenotype 2 with proba-
bility I, as expected.
134child phenotype 1 phenotype 2
parent
genotype 1 1 1
genotype 2 1 0.09
phenotype 1 0 1
phenotype 2 0 0
Table 6.1: Marginal probabilities of directed association
6.4.3 Application to real data
Modell
I then applied my algorithm to real data. I focused on using previously known associ-
ations described in Drenos et al. [63]. As summarised in tables above there is a known
association between APOB levels with APOB and APOE genotypes. CRP levels are
also associated with APOE genotype but also with CRP genotype and APOB level.
Also, smoking is highly associated with CRP level, and so it may be interesting to see
how these variables interact jointly with the addition of smoking. As with Drenos et
al, I have used log CRP and log APOB levels, as these have Gaussian distributions.
How these are related jointly will be interesting. It is expected biologically [73] that
the association between APOE genotype and CRP level is only through confounding,
and once adjusting jointly for other genotypes, this association will not be apparent.
It is unknown what the direction of association between APOB level and CRP level
is. Smoking is known only to be associated with levels of CRP, and modelling this
relationship jointly with everything else, should not affect the relationship between the
other variables. An additive APOE genotype model is associated with increased levels
of APOB level but decreased levels of CRP. APOB genotype is known to be associ-
ated with increased levels of APOB, but has no affect on CRP levels. In this subset of
variables, CRP genotype is only known to be associated with increased levels of CRP.
I ran my algorithm with these 5 variables as nodes. The data set included 2,385 individ-
uals of which 1895 individuals had no missing data at any of the 5 variables. As shown
in Section 6.2, there is no association between any of the genotypes, and therefore no
135associations between genotypes were allowed in the matrix of allowed direction. The
algorithm was run for 1 million iterations with a bum-in period of 100,000 iterations.
Note: As APOE genotype is a two SNP variant, it was coded -I, 0, 1 for c-2*, c-33and
c-4*respectively.
The table below shows the p-values associated with independent additive models be-
tween the 5 above variables and smoking status.
APOB genotype eRP genotype APOE genotype eRP level APOB level
eRP level 0.28 4.05E-03 5.2SE-05 4.25E-07
APOB level 1.60E-04 0.46 4.72E-IO 4.25E-07
Smoking 0.519 0.488 0.22 <2E-16 0.86
Table 6.2: p-values for independent tests of association
If all the independent associations shown above hold when the 5 variables (not includ-
ing smoking, initially) are modelled jointly, I would expect the following DAG
I ran the model 10 times for 1 million iterations with a bum in period of 100,000 after
which the model had converged. Plots of convergence are shown in the Appendix 9.1.
The acceptance rate of a birth, death or switch step in the MCMC was 9.4%. This
means that the algorithm is mixing well.
After a bum-in period of 100,000 iterations, the DAGs with the largest posterior prob-
abilities are as follows:
136Posterior probability of 0.18
Posterior probability of 0.15
These DAGs are both unique in terms of equivalence classes. Therefore, they have
their own underlying joint distributions.
Note: the next top models have posterior probabilities of 0.11, 0.10, 0.07 and 0.04.
The only difference between the two top models, is the addition of an association be-
tween between APOE genotype and APOB level. Considering these joint posterior
probabilities alone, this perhaps gives some indication that the relationship between
APOE genotype and CRP level is through APOB level, once modelled jointly with
the other variables. However, the marginal posterior probabilities appear to give more
information about the underlying associations.
The marginal probabilities of directed association are shown in the table below. There
are marginal posterior probabilities of 0.999 and 1that CRP genotype and APOE geno-
type are associated with CRP level respectively. There is a marginal posterior probabil-
ity of 0.45 that APOB level is dependent on APOE genotype. There is a marginal pos-
terior probability of 0.49 that CRP level is dependent on APOB level; and a marginal
137posterior probability of 0.33 that APOB level is dependent on CRP level.
child APOS level CRP level
parent
CRP genotype 0.06 0.999
APOE genotype 0.45 1
APOS genotype 0.14 0.17
APOB level 0 0.49
CRPlevel 0.33 0
The results in this table suggest that i) CRP genotype only effects CRP level. ii) CRP
level is definitely dependent on APOE genotype and iii) there is a relationship between
APOB level and CRP level. There is weaker evidence that APOB level is dependent
on APOE genotype. The direction of the association between APOB level and CRP
level is more likely to be from APOB level to CRP level. Interestingly. in this model.
APOB genotype appears to have little (or no) effect on any other variable. including
APOB level.
The model with the highest posterior probability (0.18) is log CRP level = 1.1 +(0.26*
CRP genotype) - (0.19* APOE genotype) +(0.34 * log APOB level).
In the joint model with all five variables. after adjusting for APOE genotype and CRP
genotype on CRP level there is no association between APOB genotype with APOB
level. The relationship of APOB level on the other variables in the model may be
through CRP level but perhaps not considering. In order to determine the direction of
association between APOB level and CRP level. other nodes could be added that may
act as instrumental variables. or explain in more detail the relationship.
It is strange that the marginal association between APOB genotype and APOB level
is so low. This could be because the relationship between APOE genotype. CRP level
and APOB level is so strong that once adjusted for jointly. the relationship is no longer
significant. There is something strange underlying this model but the biology behind
it is unknown. There is not enough information in this model to explain the true rela-
138tionships.
One potential idea is that APOE genotype and APOB genotype are related in some
way as this would complicate the relationships shown. However, they are not in LD
or on the same chromosome. Biologically, it is though that the association between
APOE genotype and CRP level is due to confounding. Once adjusting for other geno-
types in LD with APOE genotype, it is thought that this relationship would not exist.
However, I do not have these genotypes available, and my model can not cope with
larger numbers of variables easily.
In the absence of other information, another possibility is that the associations between
APOE genotype and CRP level are not, in fact, modulated through APOE level, for ex-
ample. I do not, however, have APOE level data and conditioning on this variable could
possibly be sufficient to identify the direction of association between APOB level and
CRP level. Another possibility to identify the direction of association between APOB
level and CRP level in this joint model is by using a confounder between the two. In
my dataset, smoking is associated with CRP level but not APOB level, and so cannot
be used as a possible confounder in the joint model. However, it is still interesting to
investigate how adding smoking to the model will effect the joint model.
6.4.4 Model2
I ran the above model but with the addition of a smoking variable. I restricted the
arrow between smoking and phenotype APOB level or CRP level to be directed from
smoking to phenotype. It is unlikely that phenotype level will have a direct effect on
smoking status. Smoking level is strongly associated with CRP level with a p-value of
<2E-16. It is also unlikely that genotype will have a direct effect on smoking status.
As shown in Table 6.2, there is no association between smoking status and any of the
genotypes in this model. (p-values of 0.52, 0.49 and 0.22 for an association between
smoking status and APOB genotype, CRP genotype and APOE genotype respectively).
Therefore, I did not allow for an arrow directly between genotype and smoking. I ran
my algorithm 10 times for 1 million iterations, a thin of 100 and a burn in of ]00,000.
139Ifall the independent associations shown above in Table 6.2 hold when the 6 variables
are modelled jointly, I would expect the following DAG
Plots of convergence are shown in Appendix 9.2. The acceptance rate of a birth, death
or switch step being accepted in the MCMC was 8.4%
The DAGs with the highest posterior probabilities were obtained for the following joint
models
1408
Posterior probability of 0.16
8
Posterior probability of 0.14
The joint relationships have similar posterior probabilities as to the model without
smoking but with the added relationship between smoking and CRP level.
Again, these DAGs have different underlying joint distributions and are members of
unique equivalence classes.
Considering the marginal posterior probabilities in the table below, it is evident that
the addition of smoking to the model does not change much.
This is reassuring in terms of the prior on model size as the increase in variables has
not altered the results significantly.
141child APOB level CRPlevel
parent
CRP genotype 0.06 0.98
APOE genotype 0.48 1
APOB genotype 0.13 0.15
Smoking 0.08 1
APOB level 0 0.49
CRPlevel 0.34 0
The joint model with the highest posterior probability (0.16) is log CRP level = 1.0+
(0.23* CRP genotype) - (0.18* APOE genotype) + (0.31 * APOB level) +(0.5 *Smok-
ing status).
6.4.5 Model3
Another set of variables with potentially interesting joint relationships as highlighted
by Drenos et al [63] are CETP genotype, APOA genotype, LPL genotype, HDL level,
TO level and smoking status. Smoking status is a known confounder of the relation-
ship between HDL level and TG level. LPL and APOA genotypes are associated with
both TO and HDL levels. CETP genotype is associated with HDL level. I used my
algorithm to investigate how these relationship workjointly.
331 individuals out of the dataset of 2,385 were missing HDL level, and 13were miss-
ing TO level.
The p-values associated with independent relationships between these variables is
shown in the table below.
CETP genotype APOA genotype LPL genotype HOL level TO level
HDL level 0.00117 0.0114 0.000228 <2.16E·16
TO level 0.283 8.09E-05 0.00263 <2.16E·16
Smoking 0.50 0.94 0.97 0.0306 0.045
142If all these independent associations occurred jointly, I would expect the following
DAG assuming a 5% significance level.
I ran the model 10 times for 1 million iterations with a burn-in of t00,000 iterations
each. The acceptance rate of a birth, death or switch step being accepted in the MCMC
was 8.3% Plots of convergence are shown in Appendix 9.3.
The DAGs with the highest posterior probabilities were obtained for the following joint
models
1438
Posterior probability of 0.11
8
8
Posterior probability of 0.09
1448
Posterior probability of 0.09
8
Posterior probability of 0.08
145Note: Joint top models shown are those that are most common. In this case no clear
model seems to have come up.
Marginal posterior probabilities of direct association between the 6 variables is shown
in the table below.
child HDL level TO level
parent
LPL genotype 0.53 0.12
CETP genotype 0.83 0.04
APOA genotype 0.15 0.88
HDL level 0 0.49
TO level 0.51 0
Smoking 0.20 0.12
In this case, my algorithm does not seem to select a particular model with high pos-
terior probability. The DAGs with the highest posterior probabilities indicate that the
association between APOA genotype and HDL level is modulated through TG level;
and the relationship between LPL genotype and TG level is modulated through HDL
level. Again, the marginal posterior probabilities give more information and in this
case re-iterate what is seen in thejoint models. There is a posterior probability of 0.53
of a direct association between LPL genotype and HDL level compared to 0.12 of a
direct association between LPL genotype and TG level. Similarly, there is a poste-
rior probability of 0.88 of a direct association between APOA genotype and TG level
whereas there is a posterior probability of 0.15 of a direct association between APOA
genotype and HDL level.
The marginal probabilities found suggest that the relationship between CETP genotype
and TG level is modulated through HDL level. Itappears that
i) HDL level is dependent on CETP genotype
ii) HDL level is dependent on LPL genotype
iii) TG level is dependent on APOA genotype
146iv) There is a relationship between TO level and HDL level
Biologically, it may have been expected that the algorithm would not pick a particular
model as the relationship between TO level and HDL level are so highly correlated.
The joint model with the highest posterior probability (0.11) is HDL level = 1.94 -
(0.07 * LPL genotype) + (0.09 * CETP genotype) - (0.45 * log TO level) where log
TG level = 0.56 + (0.11 * APOA genotype)
The DAOs with the highest posterior probabilities shown above all have unique equiv-
alence classes and therefore different underlying joint distributions. However, they all
have similar posterior probabilities so it is difficult to distinguish from them what the
true joint relationships are. The marginal posterior probabilities give more information
and given these, the only important direction that is not defined is that between HDL
level and TG level. It is likely that there are more unknown factors involved in this
highly correlated relationship. Again, my model is not able to include any more vari-
ables easily even if they were available.
As there is weak evidence of a joint model including an association between smoking
and either HDL or TG level, I dropped smoking from the dataset.
6.4.6 Model4
I ran my algorithm on the data used in Model 3 but without smoking status. Again,
I ran the algorithm 10 times for 1 million iterations and a bum-in period of 100,000.
Acceptance rate was 9%. Convergence plots are shown in Appendix 9.4. The DAOs
with the highest posterior probabilities are shown below.
147Posterior probability of 0.15
Posterior probability of 0.13
148Posterior probability of 0.13
Posterior probability of 0.13
Marginal posterior probabilities of direct association between the 5 variables is shown
in the table below.
149child HDLlevel TO level
parent
LPL genotype 0.53 0.13
CETP genotype 0.83 0.04
APOA genotype 0.15 0.88
HDLlevel 0 0.49
TO level 0.51 0
Without smoking in the model, there is a smaller subset of possible arrows in the DAG,
and therefore the posterior probabilities of a particular model are not spread so thinly.
As seen here, the posterior probabilities of the same DAGs increase by 0.02 compared
to those in Model 3. The marginal probabilities remain the same as expected.
6.5 Conclusions and Discussion
6.5.1 Simulated Data
As demonstrated by analysis on simulated datasets, my algorithm works well on small
numbers of nodes and arrow subsets. Approximately equal posterior probabilities are
obtained for simulated equivalence classes as shown by the simulated data example
with 3 nodes. Each equivalence class has a posterior probability of ~ 0.4 and the
marginal posterior probability of phenotype 1being dependent on phenotype 2 is equal
to phenotype 2 being dependent on phenotype 1 (~ 0.5).
The addition of an instrumental variable in the form of genotype 2 to the simulated
dataset gives the correct DAG with a high posterior probability of 0.92. From this
DAG is is possible to recover the direction of association between phenotype 1 and
phenotype 2 which is recovered as modelled i.e. phenotype 2 is dependent on pheno-
type 1. This DAG is in its own equivalence class and so this has helped me to determine
the correct! simulated direction of association as discussed in introduction Section 4.8.
My algorithm also recovered the coefficients as simulated. The convergence plots show
that the algorithm is mixing well and converge to the "correct" model quickly.
1506.S.2 NPHS-IIData
The results on analysis using the NPHS-II data are, as expected, not so clear as those
using the simulated data.
Modell was an analysis on thejoint relationships between APOE genotype (rs429358
+ rs7412), APOB genotype (rs585967), CRP genotype (rs309 1244), APOB level and
CRP level. The results gave two DAGS with high posterior probabilities of 0.18 and
0.15. These showed that when examining the relationships between all these variables
jointly, only 3 direct effects are important and 1of possible importance once adjusting
for the effects of all other variables in the model. The relationship between APOB
genotype and APOB level; and APOE genotype and APOB level were not important
in the joint model. These results suggest surprisingly that the relationship between
APOE genotype and APOB level appears to be modulated through CRP level. As the
two DAGs shown above for Model 1are unique in terms of equivalence classes, Ican
conclude that there is a slightly higher posterior probability of CRP level being de-
pendent on APOB level rather than the other way round, when taking into account the
underlying joint distribution with the other variables.
Looking at the marginal posterior probabilities, these probabilities re-iterate this: there
is a marginal posterior probability of 0.49 of a direct association of APOB level on .
CRP level but only 0.33 of a direct effect of CRP level on APOB level. Itis interesting
that the independent p-value of association between APOB level and APOB genotype
of 1.60E-04 compares to 0.14 marginal posterior probability when the relationship is
examined in a joint model. i.e. APOB level regressed upon both APOB genotype
and CRP level with all other variables controlled for. Also, APOE genotype has an
independent frequentist p-value of association with APOB level of 4.72E-I O. This re-
lationship has a marginal posterior probability of 0.45 under the DAG framework.
Model 2 used the same variables as Model 1 but with the addition of smoking sta-
tus. Given the strong frequentist association found between CRP level and smoking
151independently, it is not surprising that there is a marginal posterior probability of 1be-
tween these. Other than the addition of a direct association of smoking on CRP level,
the results from Model 2 change only a tiny amount from those found in Modell. The
relationship between smoking and CRP level does not affect the joint relationships be-
tween APOE genotype, CRP genotype. APOB level and CRP level.
I examined the joint relationships between LPL genotype (rs264), APOA genotype
(rs5689566), CETP genotype (rs708272), HDL level, TO level and smoking status in
Models 3 and 4. Smoking status is a known confounder between HDL level and TO
level so it was interesting to see that smoking has no relationship with either in this
model after jointly adjusting for the genotypes (in the DAOs with the highest poste-
rior probabilities reported above). Using my DAO methodology, smoking status had a
marginal posterior probability of 0.2 and 0.12 of direct association with HDL level and
TO level respectively. These relationships had independent p-values of 0.03 and 0.045.
The results from this model show that the effect of APOA genotype on HDL level is
modulated through TO. The effect of LPL genotype on TO level is modulated through
HDL genotype. Again, considering the marginal posterior probabilities, the relation-
ship between CETP genotype and TO level is also modulated through HDL level. The
independent frequentist tests of association between APOA genotype and HDL level
and TO level have p-values of 0.01 and 8.09E-05 receptively compared to marginal
posterior probabilities of 0.15 and 0.88 when modelled jointly. Similarly, the p-values
of independent association between LPL genotype and HDL and TO levels are 0.0002
and 0.003 compared to marginal posterior probabilities of 0.53 and 0.12.
The direction of association between HDL level and TO level is still undetermined. It
may be possible to establish the direction of this association if an appropriate variable
was discovered that could act as an instrumental variable. As described in Section 4.8
a variable is instrumental in this case if it is only associated with one variable through
the other. However, I do not know of any such variables at present.
Alternatively, as HDL level and TO level are so highly correlated, better plasma traits
could be used. HDL level, for example, is composed of many lipids and these could
152be incorporated.
6.5.3 Discussion
The methodology used in my joint model analysis has automatically corrected for the
effects of all variables in the model via the edges defined. By allowing the algorithm to
choose the appropriate model any confounders in the data are automatically corrected
for as well.
Given these results, it is still tricky to determine exactly what the directed joint re-
lationships are between the variables used is. Genotype information has helped to
establish some relationships. My Bayesian methodology gives a better idea of what
the underlying joint distributions are by quantifying the posterior probability of each
DAG through model selection. This adds more information than simple independent
tests of association or joint frequentist models. [74]
The above results are in the absence of any other information. It would, for example,
be interesting to examine the effects of APOE level (which is currently unavailable in
the NPHS-II dataset) on the joint model between APOE genotype, APOB genotype,
CRP genotype, CRP level and APOB level. Incorporating APOE level into this dataset
may alter the relationship between the other variables jointly. It could be, if APOE
level is strongly correlated with CRP and APOB levels, that once adjusting for APOE
level there is no direct association between APOE genotype and CRP level. This effect
could be modulated through APOE level.
In addition, biologically it is thought the relationship between APOE genotype, APOB
level and CRP level is more complex than a model with only 3 genotypes. The inclu-
sion of other genotypes in LD with APOE genotype may explain the relationship more
adequately and answer the question as to whether the apparent relationship between
APOE genotype and CRP level is only due to confounding.
It is also important to note that it is strange that in this model, the relationship between
153APOB genotype and APOB level is not important. There is something underlying this
but it is not known what. I do not know enough about the biology behind it. or have
enough information in terms of other variables to establish anything other than the re-
sults shown. I believe that the methodology used works but there is not enough in the
model! data I was given to establish sensible results. The relationship between APOE
genotype. APOB genotype, CRP genotype, APOB level and CRP level is more com-
plex than first expected.
My algorithm is limited by the number of nodes and subset of possible arrows in the
DAG model. By expanding! developing my code in another program (C++, for ex-
ample), I could achieve more computing power. The computing time for my analysis
is approximately 24 hours for 6 nodes for lmillion iterations. Again, this could be
improved by using C++. If I were able to increase efficiency greatly then I would be
able to include more possible confounders/ variables considered potentially biologi-
cally important in the model.
In order to further investigate the efficacy of my methodology, simulated data with ef-
fect sizes more similar to the typically small genetic effects expected could be used.
This would help determine whether the inconclusive results are due to the data or my
algorithm not having enough power to detect small effect sizes.
In order to better understand these relationships, I think the next development would
be to incorporate prior biological knowledge on pathway analysis. This may help to
disentangle true relationships from spurious ones. Gene pathways are now well char-
acterised with relevant information publicly available on databases such as KEGG [75J
and Gene Ontology [76].
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7
DISCUSSION
The aim of this PhD was to try to understand the factors influencing disease by trying
to disentangle genetic and phenotypic information. Ihave developed a new method for
jointly modelling genotypes and phenotypes in an attempt to disentangle complicated
relationships; and applied an already existing method to find causal SNPs for SLE
from those in very high LD. Both of these were looking for a more simple structure
underlying the data and were achieved using a Bayesian framework.
7.1 Bayesian Multivariate Adaptive Regression Spline
Modelling
I applied the Bayesian Multivariate Adaptive Regression Spline model developed by
Verzilli et al. [59] to find causal SNPs for SLE amongst those in high LD on the MHC
region. This expanded on work by Rioux et al [46] who identified primary associa-
tion signals, and then performed conditional regression to identify independent sec-
155ondary signals. They reported at least three separate signals using this method, namely
RS1269852, RS3135391 and the NOTCH gene. My method highlighted at least four
independent signals with posterior probability 0.72. These were either RS558702 or
RS1296852 with either RS3135391 or RS135388 in addition to two other signals.
There was strong evidence for two other signals along the chromosome but without
high posterior probabilities of specific SNPs. Therefore, the BMARS model allowed
me to identify further SNPs and regions of interest for further investigation. In addi-
tion, the BMARS methodology was more flexible as it allowed for genotype interac-
tions and different effects for each SNP.
7.1.1 Comparison to Other Methods
Other current methods of determining SNP association in this respect include frequen-
tist stepwise regression or the Bayesian method, Bayesian IMputation-Based Associa-
tion Mapping (Bim-Bam) [77].
Frequentist stepwise regression would only result in one model with no known cer-
tainty that it is the correct model. The Bayesian methodology used gives quantitative
posterior probabilities of each model; of the number of signals; and of each SNP hav-
ing an association. It is unlikely that a single model will represent the data. It is more
likely that a number of similar models will be almost equally representative of the un-
derlying model. BMARS quantifies the posterior probability of each of these models
using model averaging whereas a frequentist stepwise approach forces the choice of a
single model.
The Bim-Bam method shares a few similarities with BMARS. Bim-Bam is also a
method to detect causal SNPs when multiple causal variants are present. Bim-Bam
uses LD information together with typed genotypes to impute missing genotypes, and
then uses Bayesian regression to assess association between the phenotype and the es-
timated genotypes. Bim-Bam then quantifies the strength of evidence that each SNP
is associated with Bayes Factors. Therefore, like the method used in this PhD, this ap-
proach provides more interpretable explanations for observed associations. compared
156to frequentist methods or single SNP tests.
However, BMARS has several advantages over Bim-Bam in that it allows for interac-
tions between genotypes and uses a reversiblejump algorithm. The use of interactions
more accurately defines the relationships between SNPs and the outcome. The use of
reversible jump means that a BMARS approach results in model selection and actu-
ally eliminates SNPs from the model whereas Bim-Bam summarises the strength of
association of all SNPs individually. This means that with BAMRS the strength of evi-
dence for each model is quantified with a posterior probability; rather just the strength
of association for each single SNP. By selecting the most likely models, BMARS is
modelling SNPs jointly and so selects the true causal SNPs from those in high LD.
7.2 Bayesian Networks for Genetic Association Studies
The methodology I developed on Bayesian networks for genetic association studies
modelled several variables jointly; automatically correcting for the effects of all vari-
ables in the model via the edges defined. This work expanded on the independent
tests of association between SNPs and phenotypes highlighted by Drenos et al. [63]
in the NPHS-II data. The analysis I carried out gave more information about these
associations by allowing for the joint underlying distributions. Again, as I have used
a Bayesian framework, posterior probabilities of each model and marginal posterior
probabilities of association between each set of variables are achieved. The DAG
framework also allows the possibility to determine the direction of associations be-
tween variables.
7.3 Advantages of Methodology Used
Both methods in my PhD thesis make use of Bayesian statistics. In a context where
there is a lot of uncertainty about which SNP is the most causal out of those in LD, or
which association is the strongest given weak genetic effects, this has several advan-
tages as discussed above. i.e. strength of evidence quantified in posterior probabilities
157of models and marginal probabilities of associations. The priors used in my models
were uninformative and sensitivity analysis showed that the priors did not affect the
results.
7.4 Future Work
Both methods are attempting to explain complex genetic relationships. I believe that
the future of genetic research is in gene-environment interplay. More information and
methodology that allow for highly correlated factors in analysis are needed. The key to
how genetics affects diseases is in understanding how genes and environmental factors
are interlinking. Fine mapping projects using re-sequencing are emerging such as the
1,000 Genomes project [23]. This is an example of biology and genome-wide associ-
ation studies brought together. These projects collect data with complicated pathways
and there are likely to be a lot of SNPs in high LD interacting with other biological
factors to be disentangled. It is becoming more and more apparent that genes act with
other biological factors in complex pathways.
The BMARS methodology used in this PhD, in my opinion, could be helpful in iden-
tifying causal SNPs (or clusters of SNPs) for further analysis in these large, complex
datasets. The BMARS model already allows for epistatis, in that it is very flexible in
allowing for interactions between genotypes and different genotypic effects on the out-
come (due to the spline feature for dominance, additivity, etc.). The BMARS method-
ology could also easily be extended to include other factors such as multiple pheno-
types. I believe that BMARS is a computationally efficient way to establish causal
SNPs from large datasets.
My methodology for networks could be expanded to allow for more variables compu-
tationally, to investigate further these complex relationships. With more and more data
being collected, we are likely to have larger sample sizes, which would be better for
detecting small genotypic effects due to an increase in power. This would be useful
to disentangle the many questions we have about gene-environment interaction, and
direction of effects. The variables would be modelled jointly and hopefully find true
158effects from spurious ones once everything in the model has been adjusted for. The
methodology could also be extended to include nodes for genotype-phenotype interac-
tion.
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8.0.1 Data Overview
Initial analysis of the dataset showed that there were a maximum of 126 (4.3%) geno-
types missing over anyone SNP, or a maximum of 116(9.4%) missing genotypes by
individual. There were 368 SNPs (30%) with no missing genotypes and 1067(36.5%)
individuals with no missing genotypes. The plots below show the distribution of miss-
ing genotypes.
170Missing Genotype Count by Individual
Number 01Missing Genolypes
Figure 8.1: Missing genotype count by individual
Missing Genotype Count by SNP
Number 01 Missing Gonotypes
Figure 8.2: Missing genotype count by SNP
Figure8.1 shows that the majority of individuals who have any missing gen typ at
all (approximately 900) are missing only 1 genotype out of 1230 SNPS in th datas t.
As the number of genotypes missing increa es, the frequency of individual rapidly
decreases. One individual has the maximum of 116 mi ing genotype.
Figure 8.2 shows the number of individuals missing for each loci. There are 214 I 'i
with 1 individual missing a genotype. Again, as the number of individual' mi. ing
genotypes increases for each loci, the frequency of occurren e decrease. nly one
17]loci has genotypes missing for 126 individuals.
Analysis of missing genotypes within the Spanish data showed similar level of miss-
ing data.
The Spanish dataset contained genotype information for 813 individuals on 5375 SNPs
on chromosome 6. Initial analysis of the dataset showed that there were a maximum
of 42 out of 813 (5.2%) genotypes missing over anyone SNP, or a maximum of 141
missing genotypes out of 5375 (2.6%) by individual. There were 3304 (61.5%) SNPs
with no missing genotypes and 4 (0.5%)individuals with no missing genotypes. The
plots below show the distribution of missing genotypes.
Missing Genotype Count by Individual
Number or Missing Gonotypes
Figure 8.3: Missing genotype count by individual
172Missing Genotype Count by SNP
Number at Msslng Genotypes
Figure 8.4: Missing genotype count by SNP
Figure 8.3 shows that the majority of individuals who have any missing genotypes at
all (99.5% of them) are missing approximately 10 out of 5375 SNPs. As the number
of genotypes missing increases, the frequency of individuals again decreases. One in-
dividual has the maximum of 141 missing genotypes.
Figure 8.4 shows the number of individuals with a missing genotype at each loci. There
are 671 loci with 1 individual missing a genotype. As the number of individuals miss-
ing genotypes by loci increases, the frequency decreases. 1 loci has genotype mis ing
at 42 individuals.
8.1 LD Plots
1731741751768.2 Posterior Probability Plots of UK vs US Data
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Figure 8.8: Posterior Probabilities by UK and US Datasets
8.3 Posterior Densities of f3 for UK/US Analysis
Plots of posterior densities of (3 coefficients of top SNPs given they are in the UK/US
model
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1798.4 Posterior Densities of f3 for Spanish Analysis
Plots of posterior densities of J3 coefficients of RS3129768 given it is in the model
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1808.5 Convergence Plots of Combined UKIUS and Span-
ish Datasets Model
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Figure 8.9: Convergence Plot of Posterior Probability of RS3135391 having an Associa-
tion with SLE
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Figure 8.10: Convergence Plot of Posterior Probability of RS3135388 having an Associ-
ation with SLE
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Figure 8.11: Convergence Plot of Posterior Probability of RS 1269852 having an Associ-
ation with SLE
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1839.1 Convergence Plots of Model 1
All plots are for first 100,000 iterations with a thin of 100.
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Figure 9.1: Autocorrelation function
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Figure 9.2: Density plots
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Figure 9.3: Trace plots
1859.2 Convergence Plots of Model 2
All plots are for first 100,000 iterations with a thin of 100.
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Figure 9.4: Autocorrelation function
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Figure 9.6: Trace plots
1879.3 Convergence Plots of Model 3
All plots are for first] 00,000 iterations with a thin of 100.
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Figure 9.7: Autocorrelation function
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Figure 9.8: Density plots
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Figure 9.9: Trace plots
1899.4 Convergence Plots of Model 4
All plots are for first 100,000 iterations with a thin of 100.
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Figure 9.12: Trace plots
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